



## **20<sup>th</sup> IFCC - EFLM European Congress of Clinical Chemistry and Laboratory Medicine**

**45<sup>th</sup> Congress of the Italian Society of  
Clinical Biochemistry and Clinical Molecular Biology (SIBioC)**

**Milano, Italy  
Milano Convention Centre - MiCo  
19-23 May 2013**

# **Final Programme**

**The EUROMEDLAB Milano 2013 app is designed to enrich delegates' and exhibitors' experience.**



Using the app, you can display the following :

- GENERAL INFORMATION
- SCIENTIFIC PROGRAMME (with the speakers' presentations)
- POSTERS
- SPONSORS
- GALLERY

**Select your device and download the app now at  
[euromedlab.expomeeting.it](http://euromedlab.expomeeting.it)**

# CONTENTS

Auspices	4
Invitations	6
Committees	11
Congress Secretariat	13
Executive Boards	14
Bursaries and Awards	15

## SCIENTIFIC PROGRAMME pages 17-90

Week agenda	18
Opening Ceremony	22
Monday 20 May	24
Tuesday 21 May	44
Wednesday 22 May	64
Thursday 23 May	83
Closed meetings	89

## POSTERS pages 97-244

Information	98
Posters on Monday	99
Poster on Tuesday	138
Poster on Wednesday	175
Index of authors	215

## GENERAL INFORMATION pages 251-263

General map	252
General information	253
Social programme	261
Tourist information	263

## SPONSORS pages 271-330

Platinum sponsors	273
Gold sponsors	279
Silver sponsors	281
Bronze sponsors	286
Exhibitors	291
List of sponsors	325
Exhibition area map	326

*The Final Programme has been released in April 2013*



UNIVERSITÀ  
DEGLI STUDI  
DI MILANO

University of Milan



World Association of  
Society of Pathology  
and Laboratory  
Medicine (WASPaLM)



University of  
Milano-Bicocca



International Union of Pure  
and Applied Chemistry  
(IUPAC)



Vita-Salute San Raffaele  
University, Milan



International Association  
of Therapeutic Drug  
Monitoring and Clinical  
Toxicology (IATDMCT)



UNIVERSITÀ DEGLI STUDI DI PAVIA

University of Pavia



International Union of  
Biochemistry and  
Molecular Biology  
(IUBMB)



University of Insubria



Clinical and Laboratory  
Standards Institute  
(CLSI)



UNIVERSITÀ DEGLI STUDI  
DI MILANO

Centre for Traceability  
in Laboratory Medicine  
(CIRME)



European Society for  
Pharmacogenomics and  
Theranostics (ESPT)



European Ligand Assay  
Society (ELAS)



African Federation of  
Clinical Chemistry  
(AFCC)



Arab Federation of  
Clinical Biology (AFCB)



Asia-Pacific Federation for  
Clinical Biochemistry and  
Laboratory Medicine  
(APFCB)



Latin-American  
Confederation of Clinical  
Biochemistry  
(COLABIOCLI)



Balkan Clinical Laboratory  
Federation (BCLF)



Nordic Society for  
Clinical Chemistry  
(NFKK)



Ordine dei Medici di  
Milano



Ordine Nazionale dei  
Biologi

## CONGRESS PRESIDENT



Dear Colleagues,

On behalf of the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC) and of the Congress Organising Committee, it is my pleasure to welcome you to the 20<sup>th</sup> IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine (EuroMedLab) in the pavilions of the futuristic Milano Convention Centre MiCo.

Putting on this congress, which represents the most important European meeting in the field, takes more than three years of hard work by several groups of Colleagues and MZ Congressi staff. I want to particularly mention the Scientific Programme Committee, the International Scientific Advisory Board and the Abstract Evaluation Committee. I am grateful to all of them.

We are really proud of the scientific programme, which includes one Opening and four Plenary Lectures, 23 Symposia, and 48 Workshops, involving more than 200 outstanding international speakers. About 1300 posters are presented during the poster sessions, many of those by young Colleagues. Plus don't forget that there are six pre- and post-congress Satellite Meetings organised in different beautiful venues near Milan. Plenary Lectures feature internationally recognized speakers who relate to a specific disease or pathophysiologic condition, combining clinical laboratory, research and future developments with their own clinical experience. Classical symposia cover a list of important topics in medicine and clinical science, some involving young scientists who present selected oral communications. Workshops, organized in cooperation with industry, deal with more practical topics exploring several interesting emerging aspects of laboratory science.

Despite today's huge economic challenges, the EuroMedLab 2013 congress location hosts a large exhibition of diagnostic products involving 130 international and Italian companies. This permits the congress to deliver a unique mix of educational programmes and very interesting opportunities offered by the IVD market.

I especially welcome young scientists attending the congress and presenting their research findings. A number of bursary programmes have been planned to support their presence at the meeting and I hope that this effort made by the Congress Organizing Committee in cooperation with various supporting organizations is appreciated.

A very special social programme has been developed for attendees. Particularly, I would like to draw your attention to the Opening Ceremony, in which the performance of the Milan's Giuseppe Verdi Orchestra is scheduled, and to the Congress Party in the suggestive and unique venue of the Sforzesco Castle.

I hope that you enjoy the excellent scientific programme and experience the history and the culture of our dynamic city.

With warmest regards,  
*Mauro Panteghini*

## SIBioC PRESIDENT

Dear Friends and Colleagues,

2013 is a special year for the Italian Society of Clinical Biochemistry and Clinical Molecular Biology (SIBioC), as the 45th Congress of our Society will be held jointly with the 20<sup>th</sup> IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicine in the pavilions of the futuristic Milano Convention Centre MiCo.



It is my great pleasure and honor as President of SIBioC to welcome you to the EuroMedLab Milano 2013.

In preparation for the event, the Scientific Programme Committee, under the skillful presidentship of Mauro Panteghini, has worked hard to put together a programme covering all aspects of laboratory medicine. Oral presentations and symposia will provide exposure for researchers and a platform for academic exchange on exciting new topics currently under investigation.

Furthermore, in line with our tradition, we have striven to give a large number of young scientists the unique opportunity to present their work to the world's leading specialists through poster sessions and obtain precious feedback to improve their work.

A very warm welcome to all congress participants and to accompanying persons. I hope that Milano EuroMedLab 2013 will be memorable for all of you.

*Giuseppe Castaldo*

## IFCC PRESIDENT



The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) is proud to co-host EuroMedLab Milan 2013. This will be a special congress in a brand-new venue in one of the most stylish cities in Europe. The organisers have done an excellent job and everything is in place for an outstanding scientific, cultural, and social occasion.

IFCC is a global professional organization serving a worldwide partnership of clinical laboratory scientists, laboratory physicians, and specialists within the in-vitro diagnostics industry. Founded in 1952, the IFCC currently counts as members 88 national societies and 50 companies, together representing more than 35,000 laboratory medicine specialists.

In providing global leadership, the IFCC's current priorities are:

- To complement and enhance its members' activities,
- To share examples of good practice and foster the contribution and added value of clinical chemistry and laboratory medicine,
- To transcend geographic and corporate boundaries by developing global programmes for clinical chemistry and laboratory medicine,
- Through its Scientific Division, to provide a forum for standardization and traceability, by establishing reference systems to improve the quality of health care,
- Through its Education and Management Division, to provide IFCC members and the healthcare community with relevant education aimed at clinical, scientific, and management issues, especially in developing countries,
- Through its Communication and Publications Division, to communicate and promote the work and image of the IFCC to clinical laboratory scientists, physicians, and health care policy makers, worldwide.

Full details of IFCC activities can be found on the IFCC website ([www.ifcc.org](http://www.ifcc.org)).

I encourage you to participate fully in all aspects of the congress. Make an effort to form new friendships and new links with international colleagues. Set yourself the target of identifying new knowledge or new areas of practice that will help improve the quality of laboratory medicine delivered by your laboratory.

*Graham H Beastall*



## EFLM PRESIDENT

Dear Colleagues,


I am delighted to welcome you to Euromedlab 2013. The European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) is pleased to once again co-host another EuroMedLab, as well as to recognise that our president-elect, Mauro Panteghini, and his team, have brought together many excellent speakers to create an innovative scientific programme, which I am sure we will all enjoy. Of course, another incentive to participate is our host city: Milan, capital of the Region of Lombardy, with its rich history pre-dating Roman times and leading right up to the present, as a city renowned for fashion and design. This is a wonderful opportunity to visit or renew acquaintance with one of Italy's main cities.



With the opportunity to renew old acquaintances, make new ones and, together, help develop our common interest in advancing the specialty of clinical chemistry and laboratory medicine, this will be yet another memorable EuroMedLab meeting, enhanced by the undoubted attractions of Milan.

*Ian D. Watson*

## MAYOR OF MILANO



Dear Doctors, Researchers and Scientists,

It is with great pleasure that I welcome you to our fine city for EuroMedLab 2013, a major event in the scientific world that chose our city for May 2013.

As the mayor of Milano, I am proud to host this congress, which I know is the most important meeting in the field of Laboratory Medicine in Europe. The five days of the meeting will be a great opportunity for exchanging experience and finding new stimuli.

The presence of both young researchers and outstanding experts will help to highlight the advances and developments of medical techniques, which are essential to improve human health and welfare. Huge progress has been made and every day new goals are achieved in the aim to better our health. It is our duty to foster and embrace the opportunities given us by the discoveries that, precisely at the Milano congress, will – I am sure – become part of the whole scientific community's shared heritage. Our city and our country will step up with major contributions in terms of medical practice and the biomedical, biotechnology and pharmaceutical industries.

The presence in Milano of so many foreign and Italian luminaries continues to create synergies and collaborations that sustain the development of research and the solutions that research in turn provides.

I am certain that EuroMedLab Milano 2013 will also be an occasion to visit the characteristic splendors of our fair city, a city increasingly in the international spotlight as we approach the Expo 2015 world's fair.

*Giuliano Pisapia*

## Congress Organising Committee (COC)

Alberto Dolci

Ferruccio Ceriotti

Massimiliano Corsi Romanelli

Andrea Mosca

Tomris Ozben

*Executive Manager*

*Scientific Programme Chair*

*Delegate to Social Programme*

*Treasurer*

*IFCC Liaison*

## Scientific Programme Committee

Ferruccio Ceriotti (Milano, IT)

Giorgio Federici (Roma, IT)

Giampaolo Merlini (Pavia, IT)

Mario Pazzagli (Firenze, IT)

Mario Plebani (Padova, IT)

Francesco Salvatore (Napoli, IT)

Sverre Sandberg (Bergen, NO)

Ian Young (Belfast, UK)

## Promoting Committee

Pierangelo Bonini (Milano, IT)

Luigi Caimi (Brescia, IT)

Vanna Chigorno (Milano, IT)

Carlo Franzini (Milano, IT)

Gianvico Melzi d'Eril (Milano, IT)

Giampaolo Merlini (Pavia, IT)

Paolo Mocarelli (Milano, IT)

Remigio Moratti (Pavia, IT)

Andrea Mosca (Milano, IT)

Guido Tettamanti (Milano, IT)

## International Scientific Advisory Board (ISAB)

Anyla Buló (Albania)

Andrea Griesmacher (Austria)

Pierre Wallemacq (Belgium)

Kamen Tzatchev (Bulgaria)

Ana-Maria Simundic (Croatia)

Lars Bo Nielsen (Denmark)

Bernard Gouget (France)

Karl Lackner (Germany)

Christos Kroupis (Greece)

Janos Kappelmayer (Hungary)

Miriam David (Israel)

Giuseppe Lippi (Italy)

Dzintars Ozolins (Latvia)

Najdana Gligorovic Barhanovic  
(Montenegro)

Jan Lindemans (The Netherlands)

Jens Berg (Norway)

Grazyna Sypniewska (Poland)

Germano de Sousa (Portugal)

Gheorghe Benga (Romania)

Tatiana Vavilova (Russia)

Nada Majkic-Singh (Serbia)

Jan Balla (Slovak Republic)

Barbara Mozina (Slovenia)

Jose Maria Queralto (Spain)

Per Bjellerup (Sweden)

Katharina Rentsch (Switzerland)

Nazmi Ozer (Turkey)

Ian Watson (UK)

## Abstract Evaluation Committee (AEC)

Andrea Mosca (Italy), <i>Chair</i>	Gabòr Kovacs (Hungary)
Katarina Baluchova (Slovakia)	Christos Kroupis (Greece)
Jens Petter Berg (Norway)	Antonio La Gioia (Italy)
Gaetano Bernardi (Italy)	Martina Montagnana (Italy)
Nicola Bizzaro (Italy)	Michele Mussap (Italy)
Antonio Buno Soto (Spain)	Gunnar Nordin (Sweden)
Paolo Carraro (Italy)	Roberta Pacifici (Italy)
Ferruccio Ceriotti (Italy)	Franca Pagani (Italy)
Morten Dahl (Denmark)	Dirk Peetz (Germany)
Francesca Di Serio (Italy)	Lorenzo Prencipe (Italy)
Vidosava Djordjević (Serbia)	Cristopher Price (UK)
Slavica Dodig (Croatia)	Josè Maria Queraltó (Spain)
Romolo Dorizzi (Italy)	Harald Renz (Germany)
Simona Ferraro (Italy)	Demetrios Rizos (Greece)
Antonio Fortunato (Italy)	Laura Sciacovelli (Italy)
Davide Giavarina (Italy)	Christoph Seger (Austria)
Massimo Gion (Italy)	Joanna Sheldon (UK)
Silvia Gracia García (Spain)	Grazyna Sypniewska (Poland)
Walter-Michael Halbmayer (Austria)	Dominika Szoke (Italy)
Alexander Haliassos (Greece)	Elisabetta Tanzi (Italy)
Angelika Hammerer-Lercher (Austria)	Elvar Theodorsson (Sweden)
Martin Hersberger (Switzerland)	Anne Vassault (France)
Svetlana Ignjatovic (Serbia)	Ian Watson (UK)
Rob Jansen (The Netherlands)	Monica Zanussi (Italy)
Klaus Khose (Germany)	Francesco Zoppi (Italy)

## Bursary Awards Committee

Mauro Panteghini	<i>Chair</i>
Massimiliano Corsi Romanelli	<i>COC representative</i>
Ian Watson	<i>EFLM President</i>
Rob Jansen	<i>EC4 representative</i>
Francesco Caggiano	<i>A. Menarini representative</i>
Marina Di Fazio	<i>The Binding Site representative</i>
Jutta Odarjuk	<i>ThermoFisher representative</i>

## Poster Awards Committee

Ferruccio Ceriotti	<i>Chair</i>
Andrea Mosca	<i>COC representative</i>
Giuseppe Castaldo	<i>SIBioC representative</i>
Claudio Dotti	<i>ELAS representative</i>
Marina Di Fazio	<i>The Binding Site representative</i>
Roberto Galli	<i>Instrumentation Laboratory representative</i>
Jutta Odarjuk	<i>ThermoFisher representative</i>



## MZ Congressi s.r.l.

*Member of the MZ International Group (Milano, Torino, Venezia, Barcelona)  
Individual company subject to management and coordination by MZ International  
Group s.r.l.*

Via Carlo Farini 81- 20159 Milano (Italy)

**Phone:** +39 02 66802323

**Fax:** +39 02 6686699

**E-mail:** [info@milan2013.org](mailto:info@milan2013.org)

### President's Assistant

[congress.secretariat@milan2013.org](mailto:congress.secretariat@milan2013.org)

### Congress Manager

[congress.manager@milan2013.org](mailto:congress.manager@milan2013.org)

### Speakers, Guests & Bursaries

[enrica@milan2013.org](mailto:enrica@milan2013.org)

### Abstracts & Posters

[sara@milan2013.org](mailto:sara@milan2013.org)

### Companies &

### Educational Workshops

[patrizia@milan2013.org](mailto:patrizia@milan2013.org)

### Registrations

[valentina@milan2013.org](mailto:valentina@milan2013.org)

### Satellite Meetings

[milan2013.satellitemeetings@biomedia.net](mailto:milan2013.satellitemeetings@biomedia.net)





## IFCC - International Federation of Clinical Chemistry and Laboratory Medicine

Graham Beastall	<i>President</i>
Howard Morris	<i>Vice-President</i>
Jocelyn Hicks	<i>Past President</i>
Sergio Bernardini	<i>Secretary</i>
Bernard Gouget	<i>Treasurer</i>
Thomas Brinkmann	<i>Corporate Representative</i>
Larry Kricka	<i>Member</i>
Vanessa Steenkamp	<i>Member</i>
Ulisses Tuma	<i>Member</i>



## EFLM - European Federation of Clinical Chemistry and Laboratory Medicine

Ian Watson	<i>President</i>
Andrea Rita Horváth	<i>Past President</i>
Mauro Panteghini	<i>President Elect</i>
Ana-Maria Simundić	<i>Secretary</i>
Peter Schuff-Werner	<i>Treasurer</i>
Huibert Storm	<i>Member</i>
Tomáš Zima	<i>Member</i>



## SIBioC - Italian Society of Clinical Biochemistry and Clinical Molecular Biology

Giuseppe Castaldo	<i>President</i>
Roberta Pacifici	<i>Past President</i>
Ferruccio Ceriotti	<i>President Elect</i>
Marzia Galli Kienle	<i>Secretary - Treasurer</i>
Antonio Fortunato	<i>Vice-Secretary - Treasurer</i>
Anna Caldini	<i>Member</i>
Antonio La Gioia	<i>Member</i>
Francesco Maglione	<i>Member</i>
Irene Moraschinelli	<i>Member</i>
Andrea Mosca	<i>Member</i>
Giovanna Patrucco	<i>Member</i>
Giovanni Pezzuto	<i>Member</i>
Cecilia Zuppi	<i>Member</i>

## EFLM BURSARIES

1. Calibasi Gizem (Turkey)
2. Canu Giulia (Italy)
3. Cardinaels Eline (Belgium)
4. Dunlop Allan (UK)
5. Elce Ausilia (Italy)
6. Hansson Charlotte (Sweden)
7. Isgrò Maria Antonietta (Italy)
8. Martínez López De Castro Ana María (Spain)
9. Min San (UK)
10. Oliveira Rodríguez Myriam (Spain)



## EC4 BURSARIES

1. Rizou Myrto (Greece)
2. Wlazel Rafal N. (Poland)



## A. MENARINI BURSARIES

1. Omuse Goffre Amuka (Kenya)
2. Scorza Manuela (Italy)
3. Surapaneni Krishna Mohan (India)



## THE BINDING SITE BURSARIES

1. Giordano Sonia (Italy)
2. Kost Andriy (Ukraine)
3. Vilchez-Aguilera Juan Antonio (Spain)



## THERMOFISHER BURSARIES

1. Albea Brenda (Argentina)
2. Begolli Gramos (Kosovo)
3. Chakraborty Sutirtha (India)
4. D'argenio Valeria (Italy)
5. Martínez-Villanueva Miriam (Spain)
6. Ntola Vuyolwethu Comfort (South Africa)
7. Wang Bei-Tzu (Taiwan)





## MILANO BURSARY PROGRAMME

1. Brady Jennifer (Ireland)
2. Bugrov Alexey Viktorovich (Russia)
3. Depreter Barbara (Belgium)
4. González M. Santamaría (Spain)
5. Jacobs Leo (The Netherlands)
6. Jensen Christina Munch (Denmark)
7. Kovacevic Tamara (Serbia)
8. Lacevic Dzenana (Bosnia Herzegovina)
9. Mazeikiene Asta (Lithuania)
10. Mueller Daniel (Switzerland)
11. Paiva Teles Maria José (Portugal)
12. Poupouridou Nikoletta (Greece)
13. Simon Diána (Hungary)
14. Sonsala Alicja (Poland)
15. Sudmann Åshild Amelie (Norway)
16. Supak Smolcic Vesna (Croatia)
17. Tanrikulu Kucuk Sevda (Turkey)
18. Tingerides Alexis (Cyprus)
19. Vasatova Martina (Czech Republic)
20. Viikant Natali (Estonia)
21. Vuorenmaa Katariina (Finland)



## IFCC-ROCHE TRAVEL SCHOLARSHIP

1. Chittamma Anchalee (Thailand)
2. Das Saswati (India)
3. Dayanath Bolonghoge (Sri Lanka)
4. Iqbal Sahar (Pakistan)
5. Lumano Hilary (Zambia)
6. Mansour Neda Issa (Jordan)
7. Osegbe Ifeyinwa Dorothy (Nigeria)
8. Widodo Joko (Indonesia)



## THE BINDING SITE ITALIA AWARDS

- 1° ex-aequo: Lucia Paolini (Brescia, Italy)  
Elena Zani (Bologna, Italy)
- 3°: Vittoria Barchiesi (Napoli, Italy)





## SCIENTIFIC PROGRAMME

## SUNDAY, 19 MAY

<b>GOLD</b>
<b>17:00 - 20:00</b>
<b>OPENING CEREMONY</b>
<b>20:00 - 22:00</b>
<b>WELCOME PARTY</b>

## MONDAY, 20 MAY

	GOLD	SILVER	AUDITORIUM	BROWN 3	BROWN 1-2	SUITE 1	EXHIBITION HALL
09:00	<b>SYM 1</b> Biomarkers of renal function and injury	<b>SYM 2</b> Future and quality of POCT	<b>SYM 3</b> Testing for drugs of abuse	<b>SYM 4</b> Epigenetics in cancer	IFCC Harmonization in autoimmune testing		
10:00							
11:00	BREAK						EXHIBITION
	<b>GOLD</b>						
11:45	<b>PLENARY LECTURE</b> Iron metabolism and pathophysiology						
12:30	POSTER SESSION - LUNCH					<b>CLINICAL CHEMISTRY WORKSHOP</b>	
13:00	POSTER WALK DISCUSSION						
	<b>SILVER</b>	<b>AUDITORIUM</b>	<b>BROWN 3</b>	<b>BROWN 1-2</b>	<b>AMBER 5-6</b>	<b>AMBER 7-8</b>	
14:30		Educational Workshop 1	Educational Workshop 7	Educational Workshop 10	Educational Workshop 4		
15:00	<b>EFLM</b> The recognition of professional qualifications across Europe						
15:30							
15:45							
16:00		Educational Workshop 2	Educational Workshop 5	Educational Workshop 8	Educational Workshop 11	Educational Workshop 40	
16:45							
17:00							
17:15							
17:30	Educational Workshop 37	Educational Workshop 12	Educational Workshop 9	Educational Workshop 6	Educational Workshop 3	Educational Workshop 41	
18:15							
18:30							

## TUESDAY, 21 MAY

	GOLD	SILVER	AUDITORIUM	BROWN 3	BROWN 1-2	SUITE 1	EXHIBITION HALL
09:00	<b>SYM 5</b> Contemporary issues in thyroid disease	<b>SYM 6</b> Laboratory testing in neurodegenerative disease	<b>SYM 7</b> Clinical applications of quantitative mass spectrometry	<b>SYM 8</b> MicroRNAs: from bench to bedside	<b>EFLM</b> The changing landscape of the clinical evaluation of biomarkers		
10:00							
11:00	BREAK						
	GOLD						
11:45	PLENARY LECTURE Sick molecules and amyloidosis						
12:30	POSTER SESSION - LUNCH					<b>CLINICAL CHEMISTRY WORKSHOP</b>	EXHIBITION
13:00	POSTER WALK DISCUSSION						
	SILVER	AUDITORIUM	BROWN 3	AMBER 7-8	AMBER 5-6	BROWN 1-2	
14:30		Educational Workshop 13	Educational Workshop 19	Educational Workshop 16	Educational Workshop 22		
15:00	<b>IFCC</b> Public relations and the value of laboratory medicine						
15:30							
15:45							
16:00		Educational Workshop 17	Educational Workshop 20	Educational Workshop 14	Educational Workshop 23	Educational Workshop 42	
16:45							
17:00							
17:15						Educational Workshop 43	
17:30	Educational Workshop 15	Educational Workshop 38	Educational Workshop 21	Educational Workshop 24	Educational Workshop 18		
18:15							
18:30							

WEDNESDAY, 22 MAY

	GOLD	SILVER	AUDITORIUM	BROWN 3	BROWN 1-2	SUITE 1	EXHIBITION HALL
09:00	SYM 9 Biomarkers of prostate cancer	SYM 10 Novel aspects in coagulation testing	SYM 11 Gastroenterology disease in 2013	SYM 12 Next generation sequencing in laboratory diagnostics	IFCC Evidence in action: translating guideline recommendations into clinical practice		
10:00							
11:00	BREAK						
	GOLD						
11:45	PLENARY LECTURE Molecular basis and clonal evolution of myeloproliferative neoplasms						
12:30	POSTER SESSION - LUNCH					CLINICAL CHEMISTRY WORKSHOP	EXHIBITION
13:00	POSTER WALK DISCUSSION						
	SILVER	AUDITORIUM	BROWN 3	BROWN 1-2	AMBER 5-6	AMBER 7-8	
14:30		Educational Workshop 34	Educational Workshop 25	Educational Workshop 28	Educational Workshop 31		
15:00	EFLM Clinical guidelines and cardiac markers						
15:30							
15:45							
16:00		Educational Workshop 29	Educational Workshop 26	Educational Workshop 32	Educational Workshop 35	Educational Workshop 44	
16:45							
17:00							
17:15							
17:30	Educational Workshop 36	Educational Workshop 27	Educational Workshop 39	Educational Workshop 33	Educational Workshop 30	Educational Workshop 45	
18:15							
18:30							

## THURSDAY, 23 MAY

	GOLD	SILVER	AUDITORIUM	BROWN 3	BROWN 1-2
09:00					
10:00	<b>SYM 13</b> Controversies in detection and monitoring of diabetes	<b>SYM 14</b> Laboratory assessment of maternal/fetal unit	<b>SYM 15</b> Laboratory testing in bone and joint disease	<b>SYM 16</b> Emerging issues in sepsis	<b>SYM 17</b> Laboratory management and patient safety
11:00	BREAK				
	GOLD				
11:45	<b>PLENARY LECTURE</b> Acute coronary syndrome: the present and future role of biomarkers				
12:30	CLOSING CEREMONY				
13:00					

## Room Gold

17:00 - 20:00

### OPENING CEREMONY

17:00 Welcome Addresses

17:30 Awards

18:00 Concert by  
Orchestra "laVerdi" and Choir  
*Conductor: Maestro Jader Bignamini*

Verdi: *Aida, Marcia Trionfale*

Puccini: *Preludio Sinfonico Opus 1*

Verdi: *Nabucco, Va Pensiero*

Puccini: *Madama Butterfly, Coro a Bocca Chiusa*

Puccini: *Manon Lescaut, Intermezzo*

Verdi: *Traviata, Mattadori*

Verdi: *Il Trovatore, Vedi!*

*Il Coro Degli Zingari*

Rossini: *Il Barbiere Di Siviglia, Overture*

19:10 Opening Lecture  
*Keiji Tanaka*  
Pathophysiological roles of the proteasome in vertebrate

20:00 Welcome Party

## Room Gold

19:15 - 20:00

### OPENING LECTURE

Chair: *F. Ceriotti (Italy)*

### Pathophysiological roles of the proteasome in vertebrate

*K. Tanaka (Japan)*



Keiji Tanaka was born in 1949 and started his research career in 1972 with studies on the amino acid and protein metabolism in the Institute of Enzyme Research, after graduating from the Faculty of Medicine (School of Nutrition) at The University of Tokushima. He received his Ph.D. from The University of Tokushima in 1980, working on the hepatic protein metabolism. He was promoted to an assistant professor in 1976 and an associate professor in 1995 at the Institute for Enzyme Research at The University of Tokushima, and a head of the Department

of Molecular Oncology in 1996, a vice-director in 2002, and an acting director in 2006 at The Tokyo Metropolitan Institute of Medical Science. Currently, he is a director general at Tokyo Metropolitan Institute of Medical Science since 2011. He was a postdoctoral fellow at Harvard Medical School, USA (1981-1983). At present he is a guest professor of Ochanomizu Woman's University, Tokyo Medical and Dental University, The University of Tokyo Graduate School of Frontier Sciences, Juntendo University School of Medicine, Niigata University School of Medicine, and Tsubata University School of Medicine. Over the past 25 years, he focused on elucidating the structure and molecular/physiological functions of the proteasome. The discoveries of proteasomes in 1988, immunoproteasomes in 1994, hybrid proteasomes in 2000, and thymoproteasomes in 2007 are the highlights of his study. His current research interests include intracellular proteolysis mediated by the proteasome, ubiquitin, and autophagy system in eukaryotes in general. He is the author of over 350 papers in refereed journals. He was awarded the Naito Memorial Foundation Prize in 2003, the Asahi Prize, the Uehara Prize in 2004, the Toray Science Technology Prize in 2007, the Takeda Prize for Medical Science in 2009, the Japan Academy Prize in 2010, and the Keio Prize for Medical Science, 2011. He is an editorial board member of *Molecular Cell* since 2006 and *Cell* since 2009. He is the recipient of funds from The Specially Promoted Research of the Ministry of Education, Culture, Sports, Science and Technology (MEXT) and The Target Protein Project of MEXT of Japan.



9:00 – 11:00

**Room Gold**

SYMPOSIUM 1

**BIOMARKERS OF RENAL FUNCTION AND INJURY**

Chairs: *J. Delanghe (Belgium), G. Miller (USA)*

09:00 Beyond creatinine standardization

*J. Delanghe (Belgium)*

09:30 Specific proteins as renal function markers

*A. Grubb (Sweden)*

10:00 Markers for acute kidney injury

*M. Haase (Germany)*

10:30 MALDI imaging mass spectrometry: a powerful tool to support renal disease diagnosis

*V. Mainini, F. Pagni, C. Chinello, G. Bovo, G. Cattoretti, F. Ferrario, F. Magni (Italy)*

10:45 CYS327CYS polymorphisms of the pregnancy-associated plasma protein A (PAPP-A) gene is related to mortality of long term hemodialysis patients

*M. Kalousova, M. Jachymova, A. Muravska, A. Kubena, V. Tesar, T. Zima (Czech Republic)*

9:00 – 11:00

**Room Silver**

SYMPOSIUM 2

**FUTURE AND QUALITY OF POCT**

Chairs: *D. Bruns (USA), I. Watson (UK)*

09:00 Ensuring POCT quality in the community

*S. Sandberg (Norway)*

09:30 Ensuring POCT quality in the hospital environment

*R. Slingerland (The Netherlands)*

10:00 As a patient, how good do I want POCT to be?

*I. Watson (UK)*

10:30 A survey of laboratory analyses performed in primary health care in Sweden

*L. Norlund, P. Norlund, G. Nordin, M. Rotzen Östlund, H. Hansson, S. Nilsson, P. Karlsson, C. Krook Persson, K Skov-Poulsen, H. Liljenbring (Sweden)*

10:45 Errors in blood gas POCT: a method to qualify non conformities and address effective training for POCT operators

*L. Varraso, F. Stea, R. Lovero, E. Mascolo, F. Di Serio (Italy)*



9:00 – 11:00

## Auditorium

### SYMPOSIUM 3

#### TESTING FOR DRUGS OF ABUSE

Chairs: *R. De La Torre (Spain), R. Pacifici (Italy)*

- 09:00 Analytical toxicology of emerging drugs of abuse  
*F. Peters (Germany)*
- 09:30 Biomarkers of ethanol consumption  
*L. Morini (Italy)*
- 10:00 Oral fluid drug testing  
*S. Wille (Belgium)*
- 10:30 Emerging trends in drug use among young people  
*S. Pichini, E. Marchei, M.C. Rotolo, M. Pellegrini, R. Pacifici (Italy)*
- 10:45 An elevated carbohydrate-deficient transferrin (CDT) level due to phosphomannose isomerase deficiency in an asymptomatic adult woman with congenital disorder of glycosylation of the MPI-CDG subtype  
*A. Helander, J. Jaeken, G. Matthijs, G. Eggertsen (Sweden)*

9:00 – 11:00

## Room Brown 3

### SYMPOSIUM 4

#### EPIGENETICS IN CANCER

Chairs: *G. Castaldo (Italy), C. Kroupis (Greece)*

- 09:00 Epigenetic biomarkers in solid tumor detection, prognosis and management  
*K. Heichman (USA)*
- 09:30 Epigenetic biomarkers for early detection of aerodigestive tract cancers in biological fluids  
*T. Liloglou (UK)*
- 10:00 DNA hypomethylation in cancer  
*M. Fernandez Fraga (Spain)*
- 10:30 Identification and enumeration of tumor spheres cultured from circulating epithelial tumor cells in patients with solid cancers  
*M. Pizon, D. Zimon, U. Pachmann, K. Pachmann (Germany)*
- 10:45 Modulation of expression of cytokeratin-19 fragments (CYFRA 21-1) by iron and risk of lung cancer in some welders  
*O. Ige, O. Olorunsogo, B. Banjoko (Nigeria)*

9:00 – 11:00

Room Brown 1-2

IFCC SESSION

**HARMONIZATION IN AUTOIMMUNE TESTING**

Chairs: *N. Bizzaro (Italy), I. Young (UK)*

**09:00** The importance of autoantibody testing in autoimmune rheumatic disease

*P.L. Meroni (Italy)*

**09:30** Role of anti-neutrophil cytoplasmic antibodies

*C. Kallenberg (The Netherlands)*

**10:00** Anti-cyclic citrullinated peptide antibodies in autoimmunity

*G.J.M. Pruijn (The Netherlands)*

**10:30** Harmonization of autoantibody measurement

*J. Sheldon (UK)*

**Room Gold**

**11:45 - 12:30**

## PLENARY LECTURE

Chair: *C. Camaschella (Italy)*

### **Iron metabolism and pathophysiology**

*T. Ganz (USA)*



Tomas Ganz is Professor of Medicine and Pathology at the David Geffen School of Medicine at University of California, Los Angeles (UCLA). He received his BS in Physics from UCLA, PhD from the California Institute of Technology in Applied Physics and MD from UCLA. He then trained in Internal Medicine and Pulmonary/Critical Care Medicine at the UCLA Medical Center, and did his post-doctoral training there with Prof. Harvey Herschman. His major focus was on research on the biological role of peptide mediators in innate immunity and iron metabolism.

More recently, he has investigated the pathogenesis of anemia of inflammation and iron overload states, and worked on the development of hepcidin agonists and antagonists. His laboratory at UCLA has been continuously supported by grant funding from the National Institutes of Health, as well as from private foundation and biotechnology firms. He has authored more than 250 publications in refereed journals and more than 30 book chapters. Dr. Ganz has served as an Associate Editor of *Blood* (1998-2007), President of the International Bioiron Society (2009-2011) and has been a member of the Erythrocyte and Leukocyte Biology (ELB) Study Section of the National Institutes of Health. He is a co-founder of two biotechnology enterprises, Intrinsic LifeSciences and Merganser Biotech, focused on the diagnostic and therapeutic applications of hepcidin, and has been a scientific advisor to the leading pharmaceutical and biotechnology companies worldwide. He received the Marcel Simon Award of the International Bioiron Society in 2005 for the discovery of hepcidin.

In order to encourage discussions, a number of posters have been selected for the Poster Walk Discussion.

The first author of the selected poster is kindly requested to be by the poster panel from 13:00 to 14:00 to present the poster to the coordinator and the audience, within a time limit of max 4 min, plus 2 min for discussion.

## ALLERGY / AUTOIMMUNE DISEASE

Coordinator: *M. Corsi Romanelli (Italy)*

### M001

RECOMBINANT API M 1 AND API M 2 ALLERGENS FOR MEASUREMENT OF SPECIFIC IGE TO HYMENOPTERA VENOM.

*J. Bogdanovic, H. Kubota, T. Chuang, D. Hovanec-Burns (USA)*

### M002

SENSITIVITY AND SPECIFICITY OF LOW LEVEL IGE ANTIBODY VALUES IN PATIENTS ALLERGIC TO BETALACTAMS.

*B. Caruso, C. Cocco, N. Melloni, P. Bonadonna, R. Mirandola, G. Senna, M. Graziani (Italy)*

### M003

EOTAXIN-2 (CCL24) AND EOTAXIN-3 (CCL26) LEVELS IN NASAL LAVAGE OF PATIENTS WITH EOSINOPHILIC CHRONIC INFLAMMATION.

*E. De Corso, R. Penitente, M. Romanelo, M. Battista, G. Paludetti, C. Zuppi, S. Baroni (Italy)*

### M011

ASSOCIATION OF POLYMORPHISMS IN GENES ENCODING IL-4, AND ITS RECEPTOR WITH ATOPIC & NON ATOPIC DERMATITIS IN EGYPTIAN CHILDREN PATIENTS.

*Y. Hussein, F. Zahran, E. Ashour, S. Shalaby, M. Sayed, N. Bakr, A. , S. Alzahrani (Egypt)*

### M015

EUROLINE SPAC AND EUROBLOTONE: AUTOMATED MULTI-PARAMETER COMPONENT RESOLVED ALLERGY DIAGNOSTICS.

*A. Weimann, T. Löwe, C. Sarraß, P. Hartwich, W. Suer, W. Schlumberger, W. Stöcker (Germany)*

### M019

THE PREVALENCE OF ANTINEURONAL ANTIBODIES IN PATIENTS WITH PARANEOPLASTIC RHEUMATIC SYNDROME.

*L. Bagdonaite, R. Rugiene, A. Volynece, J. Dadoniene (Poland)*

### M024

CHARACTERIZATION OF THE ENTIRE CELIAC DISEASE INTESTINAL MICROBIOME BY NEXT GENERATION SEQUENCING.

*V. D'Argenio, G. Casaburi, V. Precone, C. Ciacci, J. Caporaso, L. Sacchetti, F. Salvatore (Italy)*

### M033

CCL17/THYMUS AND ACTIVATION-RELATED CHEMOKINE: A BIOMARKER FOR CHURG-STRAUSS SYNDROME?

*R. Assandri, M. Monari, A. Montanelli (Italy)*

## M035

PREVALENCE OF "RINGS RODS" AUTOANTIBODIES ON HEP-2 PREPARATIONS.

*C. Novembrino, R. Maiavacca, C. Matinato, M. Ronchi, M. Cambisano, G. Lunghi, C. Garlaschi, M. Ramondetta, A. Aghemo, E. Torresani (Italy)*

## M036

A NOVEL TECHNOLOGY FOR ANTIBODY PROFILING IN THE SEROLOGICAL DIAGNOSIS OF APS.

*D. Roggenbuck, T. Buettner, V. Somma, M. Cusini, F. Pregolato, M. Borghi, P. Meroni (Germany)*

## GENETIC DISEASE

Coordinator: *G. Castaldo (Italy)*

## M042

SMALL AMPLICONS HIGH RESOLUTION MELTING ANALYSIS (SA-HRMA) ALLOWED SUCCESSFUL GENOTYPING OF ACID PHOSPHATASE 1 (ACP1) POLYMORPHISMS IN THE ITALIAN POPULATION.

*G. Canu, A. Minucci, C. Zuppi, B. Giardina, E. Capoluongo (Italy)*

## M047

GENETIC SCREENING OF FAMILIAL HYPERCHOLESTEROLEMIA IN SOUTHERN ITALY: A PROPOSED DIAGNOSTIC FLOWCHART.

*A. D'Angelo, M. D'Agostino, M. Di Taranto, A. Ruotolo, C. Giacobbe, G. Marotta, M. Gentile, F. Jossa, A. Iannuzzi, P. Rubba, G. Fortunato (Italy)*

## M050

SCREENING FOR LARGE GENOMIC REARRANGEMENTS USING MLPA IN A COHORT OF 102 BRUGADA PATIENTS.

*C. Di Resta, A. Mongelli, S. Sala, P. Della Bella, M. Ferrari, S. Benedetti (Italy)*

## M054

DIAGNOSIS OF CONRADI-HÜNERMANNHAPPLE SYNDROME: CHOLESTEROL INTERMEDIATES MEASUREMENT, GENETIC TESTING AND HISTOLOGY NEED TO BE ASSOCIATED.

*K. Belabbas, A. Lamazière, S. Leclerc-Mercier, F. Chevy, S. Schmitt, J. Martinovic, A. Liquier, R. Mangione, A. Dompmartin, M. Barreau, J. Masliah, S. Hadj-Rabia, F. Dufernez (France)*

## M056

GENETIC TEST IN TWO PATIENTS AFFECTED BY FRUCTOSE 1,6-BISPHOSPHATASE DEFICIENCY AND MOLECULAR CHARACTERIZATION OF NOVEL MUTATIONS.

*G. Frisso, C. Cozzolino, N. Salemme, G. Parenti, G. Andria, M. Ruoppolo, F. Salvatore (Italy)*

## M072

BBS1, BBS10 AND BBS2 ARE MAJOR CAUSATIVE GENES FOR BARDETBIEDL SYNDROME IN ITALIAN PATIENTS.

*M. D'Antonio, G. Esposito, I. Tandurella, A. Crispo, F. Simonelli, V. Di Iorio, F. Salvatore (Italy)*

## M077

GENETIC APPROACH OF MLL2 GENE SCREENING MUTATIONS ASSOCIATED WITH KABUKI SYNDROME IN A SPANISH PATIENT.

*L. Pedrola, S. Climent, G. Pi, A. Sanchis, A. Martínez, Á. Zúñiga (Spain)*

## M081

ATYPICAL CYSTIC FIBROSIS: DEVELOPED A NEW GENETIC TEST FOR IDENTIFICATION OF ENAC MUTATIONS.

*A. Renesto, K. Bortolozzo, A. Albanese, A. Tamanini, C. Zampieri, M. Dehecchi (Italy)*

## M082

MOLECULAR ANALYSIS OF PATIENTS WITH ELEVATED LONG-CHAIN 3-OHACILCARNITINES ALLOWS DIFFERENTIAL DIAGNOSIS BETWEEN LCHAD AND MTP DEFICIENCY.

*C. Cozzolino, R. Romanelli, E. Scolamiero, G. Parenti, G. Andria, M. Ruoppolo, G. Frisso, F. Salvatore (Italy)*

## M083

SHORT BRANCHED CHAIN ACYL-COA DEHYDROGENASE DEFICIENCY: FROM METABOLIC STUDIES TO CHARACTERIZATION OF A NOVEL MUTATION.

*N. Salemme, C. Cozzolino, G. Frisso, D. Ombrone, E. Scolamiero, G. Parenti, G. Andria, M. Ruoppolo, F. Salvatore (Italy)*

## INFECTIOUS DISEASE

Coordinator: *M. Clementi (Italy)*

## M094

COMPARISON OF THREE COMMERCIAL METHODS FOR HUMAN PAPILLOMAVIRUS DETECTION IN CONSECUTIVE CLINICAL LABORATORY SAMPLES INCLUDING MEN AND WOMEN.

*G. Barra, M. Caixeta, V. Marques, L. Velasco, L. Abdalla, S. Costa (Brasil)*

## M095

GENOTYPIC HIV-CORECEPTOR TROPISM TESTING WITH GENO2PHENO [CORECEPTOR]: DIFFERENCES IN PREDICTION DEPENDING ON HIV-1 SUBTYPE.

*T. Berg, M. Obermeier, H. Walter, K. Korn, M. Däumer, E. Wolf, M. Stürmer, A. Thielen, C. Noah, P. Braun, R. Ehret, C. Kücherer, H. Müller, J. Eberle, R. Kaiser (Germany)*

## M098

EVALUATION OF PRESEPSIN (SCD14-ST) IN CORD BLOOD AS A MARKER FOR EARLY-ONSET NEONATAL SEPSIS.

*I. Cebreiros-López, J. Noguera-Velasco, A. Martínez-Ruiz, N. Sancho-Rodríguez, I. De Miguel-Elizaga, M. Martínez-Villanueva, J. Vilchez-Aguilera, C. Puche-Morenilla, P. Martínez-Hernández (Spain)*

## M104

PROGNOSTIC VALUE OF THYROID FUNCTION IN PATIENTS WITH SEVERE SEPSIS OR SEPSIS SHOCK.

*M. González Moral, J. Monsalve Naharro, G. Varo Sánchez, C. Andrés Fernández, L. Navarro Casado, M. Gerónimo Pardo (Spain)*

## M109

IDENTIFYING DENV-1 B-CELL EPITOPES USING PHAGE DISPLAY TECHNIQUE.

*E. Kuusela, G. Batra, U. Lamminmäki (Finland)*

## M112

HPV PREVALENCE AMONG HEALTHY ITALIAN MALE SEXUAL PARTNERS OF WOMEN WITH HPV INFECTION.

*S. Lombardi, L. Giusti, P. Castagna, I. Giannelli, M. Friggeri, P. Bay, A. Ghelardi, G. Bertacca (Italy)*

## M116

HIGH POST-TEST PROBABILITY OF PROCALCITONIN AND MID-REGIONAL PRO-ADRENOMEDULLIN PLASMA LEVELS IN THE DIAGNOSIS OF SEPSIS.

*M. Fioravanti, S. Angeletti, M. De Cesaris, G. Dicuonzo (Italy)*

## M119

INTERFERENCE OF AUTOMATED CEREBROSPINAL FLUID CELL COUNTS PERFORMED ON THE SYSMEX XT-4000I BY YEAST AND BACTERIA.

*G. Omuse, P. Makau (Kenya)*

## M130

SMALL-DENSE LDL CHOLESTEROL/LARGE-BUOYANT LDL CHOLESTEROL RATIO AS AN EXCELLENT MARKER FOR INDICATING LIPODYSTROPHY IN HIV-INFECTED PATIENT.

*P. Srisawasdi, T. Suwalak, C. Sukasem, W. Chantratita, S. Kiertiburanakul, M. Kroll (Thailand)*

## M139

EVALUATION OF PROMETHEUS INDEX IN PATIENTS COINFECTED WITH HEPATITIS C VIRUS AND HUMAN IMMUNODEFICIENCY VIRUS.

*G. Varo Sánchez, E. Martínez, J. Ontañón, M. González, A. Puerta, A. Martínez, L. Navarro (Spain)*

## ONCOLOGY 1

Coordinator: *M. T. Sandri (Italy)*

## M145

[-2]PROPSA AND PROSTATE HEALTH INDEX (PHI) IMPROVE DETECTION OF PROSTATE CANCER AT INITIAL AND REPEATED BIOPSIES IN YOUNG MEN ( $\leq$  60 YEAR OLD) PREFERENTIALLY DETECTING CLINICALLY SIGNIFICANT CANCER.

*J. Blanchet, C. Stephan, S. Vincendeau, A. Houlgatte, A. Semjonow (France)*

## M146

COST EVALUATION OF INTRODUCING THE PROSTATE HEALTH INDEX (PHI) IN THE MANAGEMENT OF PROSTATE CANCER DIAGNOSTIC.

*C. Castelli, J. Blanchet, R. Mathieu, S. Vincendeau (France)*

## M152

EVALUATION OF THE THIRDGENERATION TO SECOND-GENERATION PTH RATIO ON THE LIAISON XL (DIASORIN) AS A MARKER FOR PARATHYROID CARCINOMA.

*M. Schleck, T. Laurent, R. Gadisseur, A. Carlisi, O. Rousselle, E. Cavalier (Belgium)*

## M159

INTRATHECAL SYNTHESIS OF TUMOR MARKERS AND TREATMENT MONITORING OF CANCER PATIENTS.

*E. Corsini, M. Lazzaroni, E. Ciusani, A. Silvani, A. Porini, G. Bernardi (Italy)*

**M172**

14-3-3 THETA, A DIRECT INTERACTOR OF AF4, INFLUENCES HOXA9 EXPRESSION IN RS4;11 LEUKEMIA CELL LINE.

*G. Esposito, T. Fioretti, C. Armando, B. Cembrola, F. De Falco, F. Salvatore (Italy)*

**M182**

EVIDENCE-BASED EARLY BIOLOGICAL DETECTION OF PROSTATE CANCER: WHICH TEST TO USE AND WHY?

*P. Lamy, Y. Fulla, A. Gauchez, A. Georges, M. Haugh, S. Loric, E. Luporsi, P. Martin, V. Molinié, P. Perrin, J. Piffret, X. Rebillard, F. Thuillier (France)*

**M186**

AFFINITY IMPROVEMENT OF A UNIQUE PSA ANTIBODY USING PHAGE DISPLAY TECHNOLOGY.

*M. Liton, E. Brockmann, M. Peltola, M. Vehniäinen, E. Kuusela, U. Lamminmäki, K. Pettersson (Finland)*

**M197**

PREVALENCE AND CLINICAL SIGNIFICANCE OF ENORMOUSLY INCREASED CA 19.9 CONCENTRATIONS IN HOSPITALISED PATIENTS.

*R. Mozzi, S. Ferraro, C. Valente, M. Panteghini (Italy)*

**M199**

PEPTIDES FROM ADIPOSE TISSUE IN CHILDREN TREATED WITH STEM CELL TRANSPLANTATION.

*S. Skoczen, B. Mrozek, P. Tomasik, J. Gozdzik, K. Sztefko (Poland)*

**M201**

THE DIAGNOSTIC AND PREDICTIVE VALUE OF SERUM HUMAN EPIDIDYMIS PROTEIN 4 (HE4) AS A TUMOR MARKER IN LUNG CANCERS.

*B. Nagy Jr, H. Bhattoa, Z. Steiber, M. Csobán, M. Szilasi, G. Méhes, J. Kappelmayer, P. Antal-Szalmás (Hungary)*

## ONCOLOGY 2

Coordinator: *C. Sturgeon (UK)*

**M144**

THE INFLUENCE OF INFLAMMATION IN THE SEARCH OF DISCRIMINATORY BIOMARKERS FOR PROSTATE CANCER: A PROTEOMIC STUDY.

*S. Bergamini, L. Reggiani Bonetti, E. Monari, E. Bellei, A. Cuoghi, A. Maiorana, T. Ozben, S. Micali, M. Sighinolfi, A. Tomasi, G. Bianchi (Italy)*

**M150**

BRCA1 LOSS IN PROSTATE CANCER IS ASSOCIATED WITH METASTATIC SPREAD: NOVEL PREDICTOR OF PARP-INHIBITORY THERAPY?

*N. Bednarz, A. Semjonow, P. Osther, B. Brandt (Germany)*



## M153

DEFINITION OF THE LIMIT OF DETECTION (LOD) OF [-2]PROPSA FOR A POSSIBLE APPLICATION OF THE TEST AS EARLY MARKER OF BIOCHEMICAL RECURRENCE OF PROSTATE CANCER.

*M. Pontillo, F. Ceriotti, L. Fasoli, M. Lazzeri, G. Lughezzani, G. Lista, A. Larcher, A. Abrate, G. Fuzzi, G. Guazzoni (Italy)*

## M156

URINARY ALTERATIONS OF MALIGNANT KIDNEY TUMORS REVEALED BY PEPTIDOMIC APPROACHES.

*C. Chinello, E. Gianazza, V. Mainini, G. Albo, S. Signorini, M. Grasso, S. Ferrero, I. Zoppis, G. Mauri, S. Nicolardi, Y. van der Burgt, A. Deelder, F. Magni (Italy)*

## M165

ANALYSIS OF METHOTREXATE IN SERUM USING UPLC/MS/MS.

*M. Eastwood, P. Monaghan, Y. Thomson, L. Calton (UK)*

## M166

SERUM MALDI PROFILING FOR PANCREATIC DUCTAL ADENOCARCINOMA BIOMARKERS DISCOVERY: A PILOT STUDY.

*C. Fania, A. Barassi, R. Pezzilli, G. Melzi d'Eril, C. Gelfi (Italy)*

## M168

REFERENCE INTERVALS FOR THE NEW BRAHMS CHROMOGRANIN A (CGA) ASSAY.

*S. Ferraro, S. Mozzi, C. Michelazzo, D. Basco, M. Panteghini (Italy)*

## M173

PANCREATIC CANCER-DERIVED SOLUBLE MEDIATORS INDUCE DENDRITIC CELLS TO ACQUIRE AN IMMUNESUPPRESSIVE PHENOTYPE BY DOWNREGULATING CTLA4.

*E. Gnatta, P. Fogar, A. Aita, C. Frasson, S. Teolato, M. Facco, D. Bozzato, E. Greco, A. Padoan, F. Navaglia, S. Moz, C. Zambon, G. Semenzato, G. Basso, M. Plebani, D. Basso (Italy)*

## M196

HYPERGLYCEMIA-INDUCED S100A8 AND S100A9 EXPRESSION TARGET AKT, MTOR AND NF-KB SIGNALLING IN PANCREATIC CANCER CELLS.

*S. Moz, D. Bozzato, A. Padoan, C. Zambon, P. Fogar, C. Sperti, E. Greco, F. Navaglia, M. Pelloso, E. Rossi, C. Pasquali, M. Plebani, D. Basso (Italy)*

## M398

IDENTIFICATION OF THE SOLUBLE MANNOSE RECEPTOR IN HUMAN SERUM AS A NEW MACROPHAGERELATED BIOMARKER.

*S. Rødgaard-Hansen, A. Rafique, P. Christensen, M. Maniecki, T. Sandahl, E. Nexø, H. Møller (Denmark)*

## PHARMACOGENETICS / PHARMACOGENOMICS / TOXICOLOGY, DRUGS OF ABUSE

Coordinator: *R. Pacifici (Italy)*

### M245

INFLUENCE OF CYP2C9 POLYMORPHISM ON SERUM LEVELS OF PHENORBABITAL METABOLITES.

*A. Pivetti, L. Agnello, G. Pecoraro, F. Bazza, A. Caruso, B. Lo Sasso, C. Bellia, M. Ciaccio (Italy)*

### M248

ASSOCIATION BETWEEN THE NEW CYP3A4\*22 ALLELE AND THE PHARMACOKINETICS OF THE CYP3A4 PHENOTYPING PROBES MIDAZOLAM AND ERYTHROMYCIN.

*R. van Schaik, L. Elens, A. Nieuweboer, S. Clarke, K. Charles, A. de Graan, V. Haufried, R. Mathijssen (The Netherlands)*

### M249

EARLY IDENTIFICATION OF WARFARIN MAINTENANCE DOSAGE: A PHARMACOGENETIC ALGORITHM READY FOR CLINICAL TRANSLATION.

*C. Zambon, P. Fogar, M. Pelloso, V. Pengo, S. Moz, E. Gnatta, G. Nante, E. Tiso, R. Padrini, F. Groppa, D. Basso, M. Plebani (Italy)*

### M314

ELEVATED URINARY ARSENIC AND BLOOD LEAD LEVELS IN TURKISH MINE WORKERS.

*E. Tutkun, D. Wilson, P. Eun-Kim, H. Yilmaz, S. Abusoglu, D. Yuce, F. Yilmaz, A. Keten, V. Turksoy, T. Soylemezoglu (Turkey)*

### M317

HARMONIZATION OF CARBOHYDRATEDEFICIENT TRANSFERRIN MEASUREMENT: A MULTICENTER STUDY.

*V. Bianchi, M. Vidali, S. Secco, C. Arfini, M. Bagnati, G. Bellomo, C. Capanni, S. Castiglioni, D. De Francesco, L. Fontana, A. Malabaila, M. Marmo, S. Mengozzi, G. Micca, C. Schiatti, F. Speziani, R. Valinotto, M. Viarengo, C. Artusi, M. Zaninotto, M. Plebani (Italy)*

### M318

EVALUATION OF THE TRANSFERRIN GENETIC VARIANT FREQUENCIES IN THE POPULATION OF MODENA IN THE YEARS 2007-2011.

*C. Canali, T. Trenti, G. Manieri, N. Zelioli, D. Tonozzi, S. Lodi, V. Galli, R. Bedin (Italy)*

### M323

SYNERGISTIC ANTIBACTERIAL ACTIVITY OF ACACIA HORRIDA LEAF EXTRACTS IN COMBINATION WITH ANTIBIOTICS.

*Z. Ghedira, N. Mostapha, L. Chekir-Ghedira, K. Ghedira (Tunisia)*

### M325

SERUM CONCENTRATION OF LIVER FUNCTION INDICATORS IN HIV PATIENTS ON DIFFERENT CLASSES OF HIGHLY ACTIVE ANTIRETROVIRAL THERAPY (HAART).

*O. Idonije, O. Festus, H. Osadolor (Nigeria)*

### M327

FLUORIDE EXCESS IN A PATIENT TRANSPLANTED BONE MARROW RECEIVING LONG-TERM VORICONAZOLE.

*I. Bel Waer, W. Masri, M. Nouioui, F. Khlifi, D. Amira, A. Hédhili (Tunisia)*

## M329

SIGNIFICANT DECREASE OF PLUMBEMIA IN LEAD-EXPOSED WORKERS DUE TO EFFECTIVE PREVENTIVE MEASURES.

*F. Los, L. Kotackova, T. Zima (Czech Republic)*

## RENAL FUNCTION AND INJURY

Coordinator: *G. Miller (USA)*

## M250

COMPARISON BETWEEN IDMS TRACEABLE JAFFE AND ENZYMATIC CREATININE ASSAYS FOR ESTIMATION OF GLOMERULAR FILTRATION RATE BY THE CKD-EPI EQUATION IN HEALTHY AND DIABETIC INDIVIDUALS.

*A. Soares, A. Cheuiche, E. Camargo, L. Weinert, J. Camargo, S. Silveiro (Brazil)*

## M251

$\beta$ -TRACE PROTEIN AS MARKER FOR GLOMERULAR FILTRATION RATE (GFR) IN RENAL TRANSPLANT RECIPIENTS.

*S. Atef, A. Fattoh (Egypt)*

## M260

ASSOCIATION OF THE CIRCULATING INACTIVE FORM OF MATRIX GLA PROTEIN (DP-UCMGP) LEVELS AND ABDOMINAL AORTIC CALCIFICATION SCORE (AACS) IN HAEMODIALYSIS PATIENTS.

*E. Cavalier, R. Gadisseur, P. Lukas, A. Carlisi, P. Delanaye (Belgium)*

## M262

ROLE OF SERUM AND URINARY URIC ACID IN THE DIAGNOSIS OF SYNDROME OF INAPPROPRIATE ANTIDIURETIC HORMONE SECRETION (SIADH).

*S. Chakraborty, C. Bhattacharya (India)*

## M264

CREATININE-OR CYSTATIN C-BASED EQUATIONS TO ESTIMATE GLOMERULAR FILTRATION: IMPACT ON THE EPIDEMIOLOGY OF CHRONIC KIDNEY DISEASE.

*P. Delanaye, O. Bruyère, O. Moranne, L. Lutteri, J. Krzesinski, E. Cavalier (Belgium)*

## M266

CHRONIC KIDNEY DISEASES IN MIXED ANCESTRY SOUTH AFRICAN POPULATIONS: PREVALENCE, DETERMINANTS AND CONCORDANCE BETWEEN KIDNEY FUNCTION ESTIMATORS.

*R. Erasmus, T. Matsha, Y. Yako, M. Rensburg, M. Hassan, A. Kengne (South Africa)*

## M274

A NEW EQUATION TO ESTIMATE THE GLOMERULAR FILTRATION RATE IN CHILDREN AND ADOLESCENTS.

*L. Hoste, L. Dubourg, L. Selistre, V. De Souza, B. Ranchin, A. Hadj-Aïssa, P. Cochat, F. Martens, H. Pottel (Belgium)*

## M298

PROTEOMICS OF URINARY EXOSOMES: APPROACH TO BIOMARKERS DISCOVERY IN HEREDITARY TUBULOPATHIES.

*F. Raimondo, S. Corbetta, E. Manuli, A. Bettinelli, P. Pozzi, L. Baldi, S. Tedeschi, P. Brambilla, F. Magni, M. Pitto (Italy)*

## M300

BIOLOGICAL VARIABILITY OF URINE NEUTROPHIL GELATINASEASSOCIATED LIPOCALIN (NGAL) IN HEALTHY ADULTS.

*D. Rajdl, M. Šolcová, J. Racek, J. Trefil, M. Matějka, J. Fínek (Czech Republic)*

## M311

PLASMA NEUTROPHIL GELATINASEASSOCIATED LIPOCALIN AS A MARKER FOR EARLY DETECTION OF ACUTE KIDNEY INJURY AFTER CARDIOPULMONARY BYPASS IN KOREAN CARDIAC PATIENTS.

*Y. Yun, C. Park, H. Kim, Y. Ko, H. Moon, M. Hur (South Korea)*

## VITAMINS AND NUTRITION

Coordinator: *A. Fortunato (Italy)*

## M343

VITAMIN D DEFICIENCY IN PATIENTS BEFORE BARIATRIC SURGERY (HIGH BMI) AND SCHEDULED SURGERY PROCEDURES (NORMAL BMI).

*Z. Bartoszewicz, M. Jonas, A. Kondracka, W. Lisik, A. Chmura, M. Puzianowska-Kuznicka (Poland)*

## M344

A COMPARISON OF THE NUTRITIONAL STATUS OF HOSPITALIZED PATIENTS: NURSING HOME PATIENTS VERSUS HOME CARE PATIENTS.

*J. Ruiz Budría, I. Bolinaga Moral, W. Varona López, B. Boned Juliani (Spain)*

## M348

HYPOVITAMINOSIS D AND ASSOCIATED FACTORS IN PRESCHOOL CHILDREN IN A SUNNY COUNTRY.

*S. Chackrewarthy, E. Marasinghe, C. Abeysena, S. Rajindrajith (Sri Lanka)*

## M354

DIFFERENCES IN PREVALENCE OF DEFICIENT VITAMIN D LEVEL DEPENDING ON THE USED ASSAY.

*S. Górriz Pintado, P. Estela Burriel (Spain)*

## M355

VITAMIN D DEFICIENCY IN THE UNITED ARAB EMIRATES AND ITS GLOBAL STATUS.

*A. Haq, J. Vertanen (United Arab Emirates)*

## M358

COMPARISON OF SERUM VITAMIN B12 LEVELS WITH SERUM METHYLMALONIC ACID AND HOMOCYSTEINE.

*E. Ispir, M. Serdar, T. Ozgurtas, I. Kurt (Turkey)*

**M363**

ZINC DIETARY SUPPLEMENTATION ALTERS HEPATIC LIPID PROFILING RECORDED BY 1H NMR SPECTROSCOPY IN HIGH FAT DIET EXPOSED ADULT MICE.

*C. Kostara, P. Lekkas, V. Kalfakakou, E. Paleologos, C. Angelidis, P. Vezyraki, I. Deligiannis, E. Bairaktari (Greece)*

**M364**

IS VITAMIN D DEFICIENCY ASSOCIATED WITH INFLAMMATION IN FREE LIVING OLDER ADULTS?

*E. Laird, A. Molloy, M. Ward, H. McNulty, J. Wallace, M. Healy, E. McSorley, J. Strain (Ireland)*

**M367**

ROLE OF VITAMIN D AND FOLIC ACID IN CANCER PREVENTION.

*M. Oliveira Rodriguez, P. García Tejido, R. Venta Obaya (Spain)*

**M371**

VITAMIN D LEVELS IN ELDERLY SUBJECTS CORRELATE TO HUMORAL IMMUNITY.

*B. Sakem, Z. Stanga, U. Nydegger, C. Nock, P. Medina, M. Risch, L. Risch (Switzerland)*

**12:30 – 14:30**

**Room Suite 1**

**CLINICAL CHEMISTRY WORKSHOP ON PUBLICATION ETHICS  
AND SCIENTIFIC WRITING**

**12:30** Publication ethics

*N. Rifai (USA)*

**13:30** Guide to scientific writing

*T. Annesley (USA)*

**15:00 – 17:00**

**Room Silver**

**EFLM SESSION**

**THE RECOGNITION OF PROFESSIONAL QUALIFICATIONS  
ACROSS EUROPE**

Chairs: *S. Zerah (France), T. Zima (Czech Republic)*

**15:00** Professional mobility across European borders

*G. Wieringa (UK)*

**15:30** The EU Directive on recognition of professional qualifications –  
implications for the professions

*S. Zerah (France)*

**16:00** The common training programme for specialists in laboratory medicine

*R. Jansen (The Netherlands)*

**16:30** The EC4 Register of Specialists in Laboratory Medicine

*J.P. Brochet (France)*

14:30 – 15:30



## Auditorium

Educational Workshop 1 in cooperation with Roche Diagnostics  
**NEW DEVELOPMENTS IN PATIENT SCREENING, DIAGNOSIS AND MONITORING IN VIRAL INFECTIOUS DISEASES**

Chairs: *M. Clementi (Italy), H. Wedemeyer (Germany)*

14:30 HIV: diagnosis and drug resistance

*V. Ghisetti (Italy)*

14:50 The new era of HCV treatment and monitoring

*G. Foster (UK)*

15:10 Clinical implications of HBsAg quantification in patients with chronic hepatitis B

*P. Lampertico (Italy)*

14:30 – 15:30



## Room Amber 5-6

Educational Workshop 4 in cooperation with Randox Laboratories

**USE OF GENETIC PROFILING IN DETERMINING CARDIOVASCULAR RISK**

Chairs: *E. Capoluongo (Italy), J. Lamont (UK)*

14:30 Genetic testing for risk of coronary heart disease: fact or fiction?

*S. Humphries (UK)*

15:00 Gene-gene interactions can modify the effect of a single-nucleotide polymorphism associated with blood pressure levels

*S. Visvikis-Siest (France)*

14:30 – 15:30



## Room Brown 3

Educational Workshop 7 in cooperation with Siemens AG Healthcare Sector

**IMPROVING HOSPITALS' WORKFLOW PROCESSES THROUGH ADVANCED INFORMATICS AND AUTOMATION SOLUTIONS**

Chairs: *A. Gammie (UK), D. Giavarina (Italy)*

14:30 Automated solution in a multi-disciplinary laboratory for better processes and clinically effective service

*W. Bartlett (UK)*

15:00 Centrally managing point-of-care testing to improve patient care and standardize procedures

*G. Hall (UK)*

14:30 – 15:30

## Room Brown 1-2



Educational Workshop 10 in cooperation with Beckman Coulter  
**EFFICIENT SOLUTIONS FOR LABORATORY CONSOLIDATION,  
AUTOMATION AND IMPROVED WORKFLOW**

Chairs: *C. Dotti (Italy)*, *W. van Solinge (The Netherlands)*

- 14:30 Current and future laboratory requirements in a consolidating market  
*J. Wood (UK)*
- 14:50 Enhancing efficiency in a hub and spoke environment  
*T. Trenti (Italy)*
- 15:10 Workflow optimization with islands of automation  
*F. Wisplinghoff (Germany)*

15:45 – 16:45

## Room Amber 7-8



Educational Workshop 40 in cooperation with DiaSorin  
**DISCRIMINATING DIFFERENT FORMS OF HYPERTENSION**

Chairs: *A. Fortunato (Italy)*, *F. Veglio (Italy)*

- 15:45 Automated determination of aldosterone and renin: clinical information and methodological issues  
*D. Gruson (Belgium)*
- 16:15 Aldosterone to renin ratio: increasing demand for primary aldosteronism screening  
*M. Bidlingmaier (Germany)*

16:00 – 17:00

## Auditorium



Educational Workshop 2 in cooperation with Roche Diagnostics  
**HOW HIGH-SENSITIVE TROPONIN T AND NT-PROBNP  
MEASUREMENTS IMPACT CLINICAL PRACTICE**

Chairs: *P. Collinson (UK)*, *A. Dolci (Italy)*

- 16:00 How the use of highly sensitive troponin assays is changing our daily practice  
*J. Ordonez (Spain)*
- 16:20 The benefits of high-sensitive troponin T for the early diagnosis of acute myocardial infarction  
*C. Mueller (Switzerland)*
- 16:40 Towards a better understanding of biomarker-guided heart failure care: the PROTECT study  
*J. Januzzi (USA)*



16:00 – 17:00



## Room Brown 3

Educational Workshop 5 in cooperation with A. Menarini Diagnostics

### THE AUTOMATION OF URINARY SEDIMENT ANALYSIS

Chairs: *G. Fogazzi (Italy), T. Kouri (Finland)*

16:00 The clinical relevance of urinary sediment examination

*G. Fogazzi (Italy)*

16:20 Automated urinalysis: experience in 50,000 samples

*J. Gras (Belgium)*

16:40 Experiences of screening for urinary tract infections with the sediMAX automated digital image analyser

*R. Falbo, A. Tessari (Italy)*

16:00 – 17:00



## Room Brown 1-2

Educational Workshop 8 in cooperation with Abbott

### TOTAL QUALITY SOLUTION FOR TOTAL TESTING PROCESS (TTP)

Chairs: *M. Plebani (Italy), J. Queralto (Spain)*

16:00 Reviewing the role of lean management for error reduction in the pre-analytical part of TTP

*D. Hamer (UK)*

16:20 Role of instrument design for error reduction in the analytical process

*C. Grandone (USA)*

16:40 Role of the six sigma quality solution in TTP

*J. Westgard (USA)*

16:00 – 17:00



## Room Amber 5-6

Educational Workshop 11 in cooperation with Beckman Coulter

### FROM INNOVATION IN DIAGNOSTICS TO DAILY PRACTICE

Chairs: *G. Lippi (Italy), H. Storm (The Netherlands)*

16:00 Importance of reference intervals for the interpretation of anti-Muellerian hormone in clinical practice

*S. Nelson (UK)*

16:20 Impact of prostate health index on the management of patients with prostate cancer

*M. Lazzeri (Italy)*

16:40 New solutions for total automation of molecular diagnostic testing

*B. Spiess (USA)*

17:15 – 18:15

Room Amber 7-8



Educational Workshop 41 in cooperation with DiaSorin

## THE BENEFIT OF NEW MOLECULAR TECHNOLOGIES FOR THE RAPID DIAGNOSIS OF INFECTIOUS DISEASE

Chairs: *R. Burioni (Italy), M. Landini (Italy)*

17:15 Evaluation of quantitative-loop mediated isothermal amplification (Q-LAMP) in the follow-up of transplanted pediatric patients  
*C. Russo (Italy)*

17:45 Pre- and post-natal diagnosis of congenital cytomegalovirus infection  
*T. Lazzarotto (Italy)*

17:30 – 18:30

Room Amber 5-6



Educational Workshop 3 in cooperation with Horiba Medical

## PRACTICAL SOLUTIONS IN DIAGNOSTICS

Chairs: *G. Guidi (Italy), A. Robertson (France)*

17:30 The laboratory contribution to diagnosis and management of rhabdomyolysis  
*D. Bobilewicz (Poland)*

18:00 Umbilical cord blood analysis by automatic hematology analyzers  
*M. Hur (Korea)*

17:30 – 18:30

Room Brown 1-2



Educational Workshop 6 in cooperation with Instrumentation Laboratory

## ANTI-PHOSPHOLIPID ANTIBODIES: MECHANISMS AND LABORATORY DETECTION

Chairs: *G. Mengozzi (Italy), D. Peetz (Germany)*

17:30 Anti-phospholipid antibodies: mechanisms of action  
*P. de Groot (The Netherlands)*

17:50 Laboratory detection of lupus anticoagulants  
*A. Tripodi (Italy)*

18:10 Laboratory detection of anti-phospholipid antibodies with solid phase assays  
*K. Devreese (Belgium)*

17:30 – 18:30



## Room Brown 3

Educational Workshop 9 in cooperation with Abbott

### **CHALLENGE AND IMPACT OF IT SOLUTIONS IN MODERN LABORATORIES**

Chairs: *A. Haliassos (Greece), V. Tanjore (Germany)*

17:30 Current status and future outlook of IT solutions

*J. Kay (UK)*

18:00 Decision-making in university core labs and the support of IT

*U. Oesinghaus (Germany)*

17:30 – 18:30



## Auditorium

Educational Workshop 12 in cooperation with BD Diagnostics

### **SAMPLE STABILITY AND TRANSPORTATION: CAN YOU MEET ACCREDITATION REQUIREMENTS?**

Chairs: *V. Palicka (Czech Republic), A. Vassault (France)*

17:30 Maximizing stability of venous blood specimens

*C. Oddoze (France)*

17:50 Maximizing stability of urine samples

*T. Kouri (Finland)*

18:10 Ensuring stability through transportation

*G. Lippi (Italy)*

17:30 – 18:30



## Room Silver

Educational Workshop 37 in cooperation with Bio-Rad Laboratories

### **QUALITY INDICATORS AS USEFUL TOOL IN QUALITY CONTROL PROCEDURES**

Chairs: *G. Klee (USA), M. Plebani (Italy)*

17:30 An introduction to quality indicators

*O. Sonntag (Germany)*

17:50 The use of quality indicators to improve medical laboratory quality

*J. Barth (UK)*

18:10 Quality indicators: experience of a large laboratory

*L. Sciacovelli (Italy)*

9:00 – 11:00

**Room Gold**

SYMPOSIUM 5

**CONTEMPORARY ISSUES IN THYROID DISEASE**

Chairs: *P. Beck-Peccoz (Italy), L. Thienpont (Belgium)*

- 09:00** Molecular genetic approaches to the diagnosis of thyroid cancer  
*Y. Nikiforov (USA)*
- 09:30** Subclinical thyroid disease: is it clinically important?  
*B. Velkeniers (Belgium)*
- 10:00** Quality and standardisation issues in thyroid function testing  
*G. Beastall (UK)*
- 10:30** Diagnostic value of thyroglobulin measurement in fine-needle aspirate wash-outs of lymph nodes metastases of papillary thyroid carcinoma  
*C. Carozza, M. Raffaelli, G. Canu, D. Maccora, G. Fadda, R. Bellantone, C. Zuppi (Italy)*
- 10:45** Low T3 syndrome is associated with greater myocardial damage and mortality in patients with ST-elevation myocardial infarction  
*E. Galli, N. Botto, U. Paradossi, S. Cardullo, M. S. Parri, S. Storti, A. Taddei, G. Iervasi, S. Berti, A. Clerico (Italy)*

9:00 – 11:00

**Room Silver**

SYMPOSIUM 6

**LABORATORY TESTING IN NEURODEGENERATIVE DISEASE**

Chairs: *M. Corsi Romanelli (Italy), E. Theodorson (Sweden)*

- 09:00** Advances in the pathogenesis and diagnosis of Alzheimer's disease  
*R. Quirion (Canada)*
- 09:30** Cerebrospinal fluid biomarkers for Alzheimer's disease  
*M. Blankenstein (The Netherlands)*
- 10:00** Molecular imaging techniques in neurodegenerative diseases  
*A. Nordberg (Sweden)*
- 10:30** Application of quantitative clinical chemistry proteomics (qCCP) to amyloid peptides, tau protein and apolipoprotein E in human  
*S. Lehmann, J. Vialaret, L. Tiers, C. Delaby, J. Touchon, A. Gabelle, C. Hirtz (France)*
- 10:45** Reduced mitochondrial complex I+III activity related to the red blood cell folate levels in patients with Alzheimer's disease  
*H. Erdogan, M. Gultepe, A. Cosar, O. Ozcan, T. Muftuoglu, O. M. Ipcioglu (Turkey)*

9:00 – 11:00

## Auditorium

### SYMPOSIUM 7

## CLINICAL APPLICATIONS OF QUANTITATIVE MASS SPECTROMETRY

Chairs: *G. Federici (Italy), P. Wallemacq (Belgium)*

**09:00** LC-MS/MS for endocrine and metabolite testing in clinical laboratories  
*M. Vogeser (Germany)*

**09:30** “Trick or treat” for determination of immunosuppressive drugs by LC-MS/MS  
*P. Wallemacq (Belgium)*

**10:00** Trueness of results remains an issue in clinical use of LC-MS/MS systems  
*C. Seger (Austria)*

**10:30** Isotope dilution mass spectrometry-based determination of growth hormone for re-calibration of immunoassay IDS-ISYS  
*C. Arsene, J. Kratzsch, A. Henrion (Germany)*

**10:45** On line TLC-MALDI for the characterization of neutral and acidic glycosphingolipids: qualitative and quantitative analysis  
*E. Torretta, M. Vasso, C. Fania, S. Bergante, M. Piccoli, L. Anastasia, C. Gelfi (Italy)*

9:00 – 11:00

## Room Brown 3

### SYMPOSIUM 8

## MICRORNAs: FROM BENCH TO BEDSIDE

Chairs: *M. Ferrari (Italy), L. Kricka (USA)*

**09:00** MicroRNAs in the spotlight: understanding cancer gene dependency  
*C. Croce (Italy)*

**09:30** The role of non-coding RNAs in metastases: novel discoveries and future challenges  
*G. Calin (USA)*

**10:00** MicroRNAs as promising novel tumor biomarkers in the clinical laboratory  
*E. Lianidou (Greece)*

**10:30** An association between microRNA-155 and the HP genotype in patients with sickle cell anemia  
*M. Santos, R. Ferreira, D. Albuquerque, R. Oliveira, M. Bezerra, C. Lanaro, T. Zaccariotto, A. Araujo, F. Costa, M. Blotta, M. Sonati (Brazil)*

**10:45** Gene mutation in microRNA target sites of CFTR gene: a novel pathogenetic mechanism in cystic fibrosis?  
*F. Amato, M. Seia, S. Giordano, A. Elce, F. Zarrilli, G. Castaldo, R. Tomaiuolo (Italy)*

9:00 – 11:00

Room Brown 1-2

EFLM SESSION

**THE CHANGING LANDSCAPE OF THE CLINICAL EVALUATION OF BIOMARKERS**

Chairs: *C. Cobbaert (The Netherlands), C. Price (UK)*

**09:00** The introduction of a novel biomarker for pulmonary embolism - a parable

*P. Bossuyt (The Netherlands)*

**09:30** Manufacturer's and regulatory perspectives

*P. Zammaretti (USA)*

**10:00** Clinical and laboratory perspectives

*A.R. Horvath (Australia)*

**10:30** Policy and economic perspectives

*C. Hyde (UK)*

**Room Gold**

**11:45 - 12:30**

## PLENARY LECTURE

Chair: *F. Ceriotti (Italy)*

### **Sick molecules and amyloidosis**

*G. Merlini (Italy)*



Giampaolo Merlini, MD, is the Director of the Amyloidosis Research and Treatment Centre, and of the Clinical Chemistry Laboratories, Scientific Institute Policlinico San Matteo, Department of Molecular Medicine, University of Pavia, Italy. He was trained in clinical and laboratory investigation of monoclonal gammopathies in the Centres directed by Prof. Jan Waldenström (Lund University, Sweden, 1979-1981) and by Prof. Elliott Osserman (Columbia University, NY, 1981-1986). He is Professor of Clinical Biochemistry, Faculty of Medicine, University of

Pavia. His main research interests are the pathogenesis, natural history and treatment of monoclonal gammopathies and of systemic amyloidoses. Over the past 25 years, he focused on the development of new diagnostic approaches, of reliable biomarkers for assessing the prognosis and response to therapy, and of novel medicines for the treatment of systemic amyloidoses. His current research interests focus on the development of animal models of systemic amyloidoses and on the investigation of the molecular mechanisms underlying the cytotoxic effects of misfolded proteins. He is the author of over 300 papers in refereed journals. He is the recipient of funds from the European Community (FP6), the Italian Ministry of Health and the Italian Ministry of Research and University. He has served on a number of national and international committees and scientific societies, including as the Chair of the Committee on Plasma Proteins, International Federation of Clinical Chemistry and Laboratory Medicine (2000-2010) and he is now Member of the Executive Board of the Scientific Division of the International Federation of Clinical Chemistry and Laboratory Medicine. He is the past President of the International Society of Amyloidosis. He is the recipient of the Waldenström's Award (Stockholm, October 18, 2008) in recognition of his contributions to the scientific understanding of Waldenström's macroglobulinemia.

Tuesday 21

In order to encourage discussions, a number of posters have been selected for the Poster Walk Discussion.

The first author of the selected poster is kindly requested to be by the poster panel from 13:00 to 14:00 to present the poster to the coordinator and the audience, within a time limit of max 4 min, plus 2 min for discussion.

## CRITICAL CARE / EMERGENCY MEDICINE

Coordinator: *TBD*

### T001

COST-BENEFIT ANALYSIS OF COPEPTIN COMBINED WITH TROPONIN I FOR EXCLUSION OF ACUTE MYOCARDIAL INFARCTION.

*G. Alberto, D. Cosseddu, L. Arnaldi, C. Runzo, S. Musolino, S. Di Matteo, G. Bruno, G. Colombo, A. Soragna, M. Migliardi (Italy)*

### T002

S100B BLOOD LEVEL MEASUREMENT TO EXCLUDE CEREBRAL LESIONS AFTER MINOR HEAD INJURY: THE MULTICENTER STIC-S100 FRENCH STUDY.

*J. Beaudoux (France)*

### T003

PRESEPSIN (SCD14-ST) AND OTHER INFLAMMATORY MARKERS IN CRITICALLY ILL PATIENTS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME (SIRS).

*H. Brodska, K. Malickova, J. Valenta, Z. Stach, K. Pelinkova, H. Benakova, T. Zima (Czech Republic)*

### T009

MELATONIN: POSITIVE EFFECTS ON HIGH-RISK PATIENTS WITH DESYNCHRONIZED SLEEP-WAKE RHYTHM.

*E. Finati, G. Mistraretti, G. Iapichino, F. Frascini, R. Paroni (Italy)*

### T011

EVALUATION OF C-REACTIVE PROTEIN AND PROCALCITONIN TO PREDICT BACTEREMIA IN PATIENTS WITH CHEMOTHERAPY ASSOCIATED FEBRILE NEUTROPENIA IN THE EMERGENCY DEPARTMENT.

*L. García de Guadiana, M. Viqueira, R. Carbonell, P. Esteban, A. Hernando, I. Español, P. Cerezueta, C. Pérez Crespo, M. Albaladejo, J. Artero, M. González (Spain)*

### T012

INFLAMMATORY RESPONSE IN THORACIC SURGERY USING TWO DIFFERENT ANESTHETICS.

*A. Jerin, I. Potočnik, V. Novak-Jankovič, M. Skitek (Slovenia)*

### T013

BIOMARKERS POTENTIALLY DETECTING SEPSIS RAPIDLY IN INTENSIVE CARE AND EMERGENCY MEDICINE.

*G. Kost, N. Tran (USA)*



## T017

OPTIMAL CUTOFF OF PROCALCITONIN FOR PREDICTION OF BACTEREMIA IN PATIENTS WITH SUSPECTED INFECTION IN EMERGENCY DEPARTMENT.

*L. García de Guadiana, M. Viqueira, P. Esteban, A. Hernando, J. Gómez, A. de Béjar, E. Martín, Adell J, L. Martínez, E. Jiménez, M. Albaladejo, J. Artero (Spain)*

## T021

DIAGNOSTIC AND PROGNOSTIC VALUE OF SUPAR IN PATIENTS WITH SEPSIS IN COMPARISON TO PRESEPSIN AND PROCALCITONIN.

*E. Spanuth, B. Ivandic, H. Ebel, K. Werdan (Germany)*

## T027

CELL-FREE DNA AND THE PROGNOSIS OF MILD TBI PATIENTS.

*E. Trujillo Arribas, P. Camacho Martinez, A. Rodriguez Rodriguez, J. Egea Guerrero, A. Rubio, H. Macher Manzano (Spain)*

## ENDOCRINOLOGY

Coordinator: *G. Beastall (UK)*

## T032

PLASMA FREE METANEPHRINES ANALYSIS USING SPE-LC-MS/MS IN CLINICAL LABORATORY: DEVELOPMENT AND VALIDATION METHOD.

*G. Antonelli, C. Artusi, M. Marinova, L. Brugnolo, M. Zaninotto, M. Plebani (Italy)*

## T034

COMPARISON OF FOUR COMMERCIALY AVAILABLE THYROXINE (T4) IMMUNOASSAYS TO LC-MS/MS IN SERUM FROM NONPREGNANT AND PREGNANT FEMALES.

*N. Baumann, C. Fantz, J. Hines, B. Hendrix, K. Ness, A. Algeciras-Schimmich (USA)*

## T035

MEASUREMENT OF DEHYDROEPIANDROSTERONE SULPHATE (DHEAS): A COMPARISON OF ISOTOPE-DILUTION LIQUID CHROMATOGRAPHY TANDEM MASS SPECTROMETRY (ID-LC-MS/MS) AND SEVEN CURRENTLY AVAILABLE COMMERCIAL IMMUNOASSAYS.

*R. Büttler, A. Kruit, M. Blankenstein, A. Heijboer (The Netherlands)*

## T039

TESTOSTERONE CONCENTRATIONS IN MEN WITH FINASTERIDE ADVERSE SIDE-EFFECTS OVER SIX-MONTHS AFTER DRUG DISCONTINUATION.

*S. Cauci, F. La Marra, G. Mazzon, G. Chiriaco, S. Mazzolini, G. Barbina, G. Stel, C. Trombetta (Italy)*

## T048

A RAPID AND SELECTIVE METHOD FOR THE MEASUREMENT OF TESTOSTERONE IN HUMAN SERUM IN 10 SECONDS USING LASER DIODE THERMAL DESORPTIONDIFFERENTIAL ION MOBILITY SPECTROMETRY-TANDEM MASS SPECTROMETRY (LDTD-DMS-MS/MS).

*M. Jarvis, E. McClure, P. Picard, S. Auger, G. Blachon, J. Botelho, Y. Wang (Canada)*

## T052

ROUTINE SERUM STEROID PROFILING USING LIQUID CHROMATOGRAPHY MASS SPECTROMETRY BASED IVD REAGENT KIT.

*A. Nonnato, M. Puccinelli, M. Lucchiari, F. Settanni, R. Bozic, G. Mengozzi (Italy)*

## T060

ASSESSING THE STEROID PROFILE IN KLINEFELTER SYNDROME: THE IMPORTANCE OF THE CHOICE OF RELIABLE LABORATORY ASSAY.

*L. Roli, E. Baraldi, E. Dall'Olio, S. Belli, F. Fanelli, T. Trenti, U. Pagotto, M. Simoni (Italy)*

## T061

ASSOCIATION OF THE ADIPONECTIN GENE RS1501299 VARIANT WITH POLYCYSTIC OVARY SYNDROME IN CHILEAN WOMEN.

*L. Salazar, B. Vejar, J. Pailahuque, P. Valdés (Chile)*

## T064

UNUSUAL CAUSE OF DELAYED PUBERTY.

*V. Ntola, S. Govender, M. Turzyniecka (South Africa)*

## T066

HOLOTRANSCOBALAMIN AS AN EARLIER INDICATOR OF VITAMIN B12 DEFICIENCY IN THYROGASTRIC SYNDROME.

*L. Vranken, E. Cavalier, H. Valdes Socin (Belgium)*

## LABORATORY ERRORS AND PATIENT SAFETY

Coordinator: *M. Plebani (Italy)*

## T069

HETEROPHILIC ANTIBODIES INTERFERENCE IN TSH ASSAY: AN INTERESTING CLINICAL CASE.

*E. Baraldi, L. Valerio, S. Tagliavini, D. Carra, M. De Santis, L. Roli, T. Trenti (Italy)*

## T070

THE EFFECTS OF PNEUMATIC TUBE SYSTEM ON SOME LABORATORY PARAMETERS.

*M. Bekmez, A. Ayhan Harmansa, E. Kocaturk, C. Bayrak, O. Alatas (Turkey)*

## T072

THE ANALYSIS PROCESS OF DNA SEQUENCING BASED TESTS FROM FFPE TUMOUR TISSUES FOR TARGETED THERAPIES IN CANCER MANAGEMENT: DOKUZ EYLUL UNIVERSITY MOLECULAR ONCOLOGY LABORATORY EXPERIENCE.

*G. Calibasi, Y. Baskin, O. Sagol, H. Ellidokuz (Turkey)*

## T073

THE ANALYSIS PROCESS OF DNA SEQUENCING BASED TESTS FROM FFPE TUMOUR TISSUES FOR TARGETED THERAPIES IN CANCER MANAGEMENT: DOKUZ EYLUL UNIVERSITY MOLECULAR ONCOLOGY LABORATORY EXPERIENCE.

*G. Calibasi, Y. Baskin, O. Sagol, H. Ellidokuz (Turkey)*

## T075

CAN THE INCOMPLETE SERUM SEPARATION ON GEL TUBE VACUTAINERS LEAD TO THE DIAGNOSIS OF MULTIPLE MYELOMA ?

*S. Chakraborty (India)*

## T078

THE EFFECT OF ELECTRONIC REQUESTING ON PRE-ANALYTICAL ERRORS IN PRIMARY CARE.

*H. Turner, A. Dunlop, K. Deans, B. Croal (UK)*

## T087

RECORDING, MONITORING AND MANAGING PRE-ANALYTICAL ISSUES IN A METROPOLITAN UNIVERSITY HOSPITAL.

*R. Mozzi, A. Carnevale, C. Valente, A. Dolci, M. Panteghini (Italy)*

## T093

IFCC PROJECT "MODEL OF QUALITY INDICATORS": A METHOD FOR RESULTS EVALUATION.

*L. Sciacovelli, A. Padoan, A. Aita, M. Plebani (Italy)*

## T095

IMPROVING OUTPATIENT SAFETY BY A MDRD-GUIDED ADJUSTMENT ON DRUG DOSAGE BY COMMUNITY PHARMACISTS.

*E. van Wijk, A. Loef, M. ter Laak (The Netherlands)*

## T097

PRE-ANALYTICAL ERROR RATES: IMPACT OF PROVIDING FEEDBACK TO LABORATORY USERS.

*J. Glaysher, I. Watson, A. Wootton (UK)*

## NEUROLOGICAL DISEASE

Coordinator: *E. Theodorsson (Sweden)*

## T137

CLINICAL UTILITY OF IMMUNOGLOBULIN FREE LIGHT CHAINS MEASUREMENT IN CSF.

*G. Bernardi, G. Del Mese, M. Lazzaroni, E. Corsini, E. Ciusani, S. Di Ciocia, F. Taroni (Italy)*

## T138

AMINOACID PROFILE IN PLASMA DURING THE ACUTE PHASE OF STROKE.

*C. Andrés, G. Serrano-Heras, O. Ayo, I. Díaz-Maroto, S. Arteaga, M. González, L. Navarro, T. Segura (Spain)*

## T140

DECREASED HEME OXYGENASE ACTIVITY IN PATIENTS WITH ALZHEIMER'S DISEASE.

*B. Çataloğlu, M. Gültepe, A. Coşar, T. Müftüoğlu, O. İpçioğlu (Turkey)*

## T143

DETERMINATION OF KFLC AND K INDEX IN CEREBROSPINAL FLUID: A VALID ALTERNATIVE IN MONITORING INTRATHECAL IMMUNOGLOBULIN SYNTHESIS.

*F. Duranti, A. De Stefano, D. Centonze, F. Buttari, S. Bernardini, M. Dessi (Italy)*

**T146**

DE NOVO MITOCHONDRIAL DNA ALTERATION IN CHILD WITH COMPLEX NEUROLOGICAL COMPROMISSION.

*C. Mazzaccara, M. Ferrigno, M. Masullo, S. Papa, I. Pierucci, L. Sacchetti, F. Salvatore (Italy)*

**T150**

A SENSITIVE AND SELECTIVE LC-ION MOBILITY-MASS SPECTROMETRIC ANALYSIS OF ALLOPREGNANOLONE AND ITS ISOMERS IN HUMAN PLASMA OR SERUM.

*W. Jin, M. Jarvis, M. Weinstock, M. Altamus (USA)*

**T157**

OXYSTEROLS AND CHOLESTEROL METABOLISM IN NEURODEGENERATION. EVIDENCE FOR ANABOLIC IMPAIRMENT.

*V. Leoni, C. Caccia, A. Nauti (Italy)*

**T162**

LOWER ENZYME ACTIVITIES OF METHYLENETETRAHYDROFOLATE REDUCTASE(MTHFR) IN PATIENTS WITH FIRST EPISODE PSYCHOSIS AND SCHIZOPHRENIA INDEPENDENT OF MTHFR C677T AND A1298C MUTATIONS.

*T. Muftuoglu, O. Ozcan, O. Ipcioglu, A. Ates, M. Gultepe (Turkey)*

**T166**

INITIAL EVALUATION OF A NEW ANALYTICAL PLATFORM FOR THE ANALYSIS OF AB-42 AND TAU BIOMARKERS IN CEREBROSPINAL FLUID.

*S. Salamone, K. Blennow, H. Zetterberg, I. Barburina, D. Kozo, G. Green, H. Soares, P. Contestable, L. Di Magno (USA)*

**T171**

DEVELOPMENT OF PRELIMINARY CUTPOINTS FOR PROGRESSION FROM MILD COGNITIVE IMPAIRMENT TO ALZHEIMER'S DEMENTIA FOR THE VITROS® AB-42 AND VITROS TAU IMMUNOASSAYS.

*H. Soares, I. Baburina, D. Kozo, S. Salamone, G. Green, L. DiMagno, P. Contestable, H. Zetterberg, K. Blennow (Sweden)*

## PAEDIATRIC LABORATORY MEDICINE / PREGNANCY AND NEONATOLOGY

Coordinator: *K. Kohse (Germany)*

**T182**

A CLINICALLY RELEVANT MONOCLONAL GAMMOPATHY IN PEDIATRIC AGE.

*A. Dolci, I. Infusino, D. Dilillo, E. Galli, G. Zuccotti, M. Panteghini (Italy)*

**T192**

LYMPHOCYTE SUBSETS AND ACTIVATION MARKERS IN CHILDREN WITH IMMUNODEFICIENCIES AND RECURRENT INFECTIONS.

*G. Pantano, F. Tosato, G. Bucciol, M. Putti, B. Barbin, G. Marangi, M. Sanzari, M. Plebani (Italy)*

**T194**

TUMOR NECROSIS FACTOR ALPHA (TNFA) PROMOTER HAPLOTYPE CONCURS WITH HLA-DQA1 –DQB1 IN DETERMINING CELIAC DISEASE RISK.

*E. Rossi, C. Zambon, F. Navaglia, E. Greco, D. Bozzato, M. Pelloso, A. Padoan, A. Aita, P. Fogar, S. Moz, E. Gnatta, A. Tessari, G. Guariso, D. Basso, M. Plebani (Italy)*

**T198**

NEWBORN HAEMOGLOBINOPATHY SCREENING USING TANDEM MASS SPECTROMETRY IN SOUTHERN SPAIN.

*R. Yahyaoui, A. Dayaldasani, J. Sánchez-Alarcón, I. Rueda, M. Arrebola, V. Pérez-Valero (Spain)*

**T199**

QF-PCR AS A RAPID TECHNIQUE FOR ROUTINE PRENATAL DIAGNOSIS OF FETAL ANEUPLOIDIES.

*S. Atef, S. Hafez, S. Helmy (Egypt)*

**T207**

CORRELATION BETWEEN LIPID AND HORMONAL PROFILE AND INTIMA MEDIA THICKNESS AT DELIVERY IN PREGNANCIES COMPLICATED BY INTRAUTERINE GROWTH RESTRICTION.

*C. Cosma, D. Faggian, M. Zaninotto, S. Visentin, E. Cosmi, A. Lapolla, M. Plebani (Italy)*

**T211**

NONINVASIVE PRENATAL DIAGNOSIS OF CYSTIC FIBROSIS.

*S. Galbiati, A. Monguzzi, N. Soriani, F. Lalatta, M. Seia, F. Damin, M. Cretich, M. Chiari, M. Ferrari (Italy)*

**T220**

SELECTIVE TRANSFERT OF A SINGLE BLASTOCYST STAGE EMBRYO: A COMPARISON VITRIFICATION / SLOW FREEZING.

*M. Kuentz, L. Janny, H. Pons-Rejraji, A. Gremeau, L. Dejou-Bouillet, J. Pouly, F. Brugnon (France)*

**T228**

ANALYSIS OF SERUM PROTEIN FRACTIONS FROM WOMEN WITH RECURRENT PREGNANCY LOSS.

*L. Nowak-Łos, G. Odrowaz-Sypniewska, J. Zegarska, M. Zalewska-Zacharek, J. Ktyszejko-Molska (Poland)*

**T233**

EVALUATION OF 2ND TRIMESTER BIOCHEMICAL AND ULTRASONOGRAPHIC MARKERS FOR THE PREDICTION OF PREECLAMPSIA.

*D. Rizos, G. Karampas, A. Haliassos, D. Hassiakos, K. Panoulis, G. Mastorakos, N. Vitoratos, M. Rizou (Greece)*

## QUALITY ASSESSMENT, STANDARDIZATION, TRACEABILITY

Coordinator: *G. Nordin (Sweden)*

### T244

INTERPRETATION OF APTT PROLONGATION – A POSTANALYTICAL EXTERNAL QUALITY ASSESSMENT SURVEY OF 16 COUNTRIES.

*E. Ajzner, D. Rogic, P. Meijer, A. Kristoffersen, E. Somen, A. Faria, P. Carraro, J. Watine, S. Sandberg (Hungary)*

### T252

EVALUATION OF THE VERIGENE RESPIRATORY VIRUS PLUS NUCLEIC ACID TEST (RV+) FOR RAPID DETECTION OF INFLUENZA VIRUSES.

*C. Gae Ryung, L. Chae Seung (South Korea)*

### T257

COMMUTABILITY OF TWO REFERENCE MATERIALS FOR TWO COMMERCIAL LITHIUM ASSAYS.

*E. Frusciante, I. Infusino, C. Ferrero, M. Panteghini (Italy)*

### T260

EVALUATION OF THE IMPACT OF STANDARDIZATION PROCESS ON THE QUALITY OF SERUM CREATININE DETERMINATION IN ITALIAN LABORATORIES.

*I. Infusino, A. Carobene, F. Ceriotti, E. Frusciante, M. Panteghini (Italy)*

### T262

COMPARING, BY USING SIX SIGMA LEVEL OF THE ANALYTICAL PERFORMANCES OF DIFFERENT LABORATORIES WHICH USE VARIOUS ANALYZERS OF BIOCHEMISTRY.

*O. Gulbahar, M. Kocabiyik, M. Ciraci, M. Cingirt, C. Demirtas, F. Ucar, N. Bayraktar, F. Akbiyik, M. Yavuz Taslipinar (Turkey)*

### T265

A TWO-YEAR EXPERIENCE OF IMPLEMENTING GENETICAL EXTERNAL QUALITY CONTROL FOR RHD FETAL GENOTYPING BY CNRHP.

*N. R. Da Silva, S. Huguët-Jacquot, C. Toly-Ndour, A. Cortey, B. Carbonne, A. Mailloux (France)*

### T266

IMPLEMENTATION OF A PROFICIENCY TESTING FOR THE ASSESSMENT OF THE PREANALYTICAL PHASE OF BLOOD RNA.

*F. Malentacchi, K. Guenter, P. Verderio, S. Pizzamiglio, C. Ciniselli, A. Tichopad, M. Kubista, R. Wyrich, M. Pazzagli, S. Gelmini (Italy)*

### T267

HARMONIZATION OF AN LC-MS/MS ASSAY FOR THERAPEUTIC DRUG MONITORING OF THE IMMUNOSUPPRESSANT DRUG TACROLIMUS.

*D. Mason, T. Annesley, E. Champarnaud, C. Mussell, L. Harter, L. Calton, D. McKeown (USA)*

### T279

EMPOWER YOUR LAB - NEW INTEGRATED EQA DESIGN.

*H. Stepman, U. Tiikkainen, L. De Grande, J. Pelanti, D. Stöckl, H. Laitinen, L. Thienpont (Belgium)*

### T281

UK NEQAS PILOT SCHEME FOR ANTIMÜLLERIAN HORMONE – EARLY EXPERIENCE.

*N. Syme, R. Al-Sadie, C. Sturgeon (UK)*

## TECHNOLOGY, INSTRUMENTATION AND METHOD EVALUATION / LABORATORY MANAGEMENT AND INFORMATION TECHNOLOGY 1

Coordinator: *F. Zoppi (Italy)*

### T116

SPIDIA-RNA: FIRST EXTERNAL QUALITY ASSESSMENT FOR THE PREANALYTICAL PHASE OF BLOOD SAMPLES USED FOR RNA BASED ANALYSES.

*F. Malentacchi, L. Simi, C. Orlando, R. Wyrich, K. Guenther, C. Hartmann, P. Verderio, S. Pizzamiglio, C. Ciniselli, A. Tichopad, M. Kubista, S. Gelmini, M. Pazzagli (Italy)*

### T119

HOW TO PROCESS BLOOD SAMPLES FASTER IN A ROUTINE CLINICAL BIOCHEMISTRY LAB.

*C. Munch Jensen (Denmark)*

### T127

OPTIONS FOR IMPROVING TURNAROUND: COMPARISON OF POINT-OF-CARE AND RAPID SERUM TUBE FOR CHEMISTRY TESTS.

*C. Snozek, R. Orr, J. Uy, J. Hernandez (USA)*

### T288

CELIAC DISEASE DIAGNOSIS AND MONITORING: COMPARISON BETWEEN CHEMILUMINESCENCE AND ELISA ANTITRANSGLUTAMINASE AND ANTIDEAMIDATED GLIADIN PEPTIDES MEASUREMENTS.

*A. Aita, D. Basso, E. Rossi, M. Pelloso, G. Guariso, C. Zambon, F. Navaglia, E. Greco, D. Bozzato, A. Padoan, P. Fogar, M. Plebani (Italy)*

### T292

NEW INSTRUMENT FOR EASY DETERMINATION OF RHEOLOGICAL PARAMETERS OF ERYTHROCYTES.

*B. Albea, A. Marenzana, H. Castellini, B. Riquelme (Argentina)*

### T296

THE CONVENIENT PURIFICATION OF BIOCONJUGATED UPCONVERTING NANOPARTICLES BY HIGH GRADIENT MAGNETIC SEPARATION.

*R. Arppe, O. Salovaara, L. Mattsson, S. Lahtinen, T. Soukka (Finland)*

### T308

ABILITIES OF THE FACTOR FOR CORRELATING DIMENSION® JAFFE CREATININE METHOD TO THE IDMS REFERENCE MEASUREMENT PROCEDURE IN ASSESSMENT OF CHRONIC KIDNEY DISEASE.

*A. Chittamma, S. Vanavanan, C. Kitiyakara, M. Rochanawuttanon (Thailand)*

### T323

ACCURACY OF THREE AUTOMATED 25-HYDROXYVITAMIN D ASSAYS IN HAEMODIALYSIS PATIENTS.

*B. Depreter, A. Heijboer, M. Langlois (Belgium)*

### T328

DEVELOPMENT OF A RAPID AUTOMATED SPE PROCEDURE FOR THE MEASUREMENT OF PLASMA COTININE BY LC-MS/MS.

*A. Dunlop, I. Clunie, D. Stephen, J. Allison (UK)*

**T361**

HOMOGENOUS HLA-DQA1\*05 PCR ASSAY BASED ON SWITCHABLE LANTHANIDE FLUORESCENCE PROBES.

*A. Lehmusvuori, M. Kiviniemi, T. Soukka (Finland)*

**TECHNOLOGY, INSTRUMENTATION AND METHOD EVALUATION / LABORATORY MANAGEMENT AND INFORMATION TECHNOLOGY 2**

Coordinator: *A. Vassault (France)*

**T099**

THE COST OF POOR SAMPLE QUALITY: ASSESSING THE FINANCIAL IMPACT OF SAMPLE REJECTION AND RECOLLECTION IN HEALTHCARE INSTITUTIONS.

*G. Chait, K. Schlueter, E. Baginska, K. Scraba, L. Flynn, S. Church (UK)*

**T125**

STRATEGIES TO IMPROVE CLINICAL LABORATORY OUTCOMES THROUGH BALANCED SCORECARD MANAGEMENT SYSTEM: TEN YEARS EXPERIENCE.

*M. Salinas, M. Lopez-Garrigos, M. Gutierrez, J. Lugo, A. Santo-Quiles, L. Flors, C. Leiva-Salinas (Spain)*

**T290**

SIMULTANEOUS DETERMINATION OF SIROLIMUS AND EVEROLIMUS BY LCMS/MS AUTOMATED PROCEDURE: A FOUR-YEAR EXPERIENCE IN KIDNEY TRANSPLANTATION RECIPIENTS.

*H. Akbas, A. Dinckan, H. Kocak, G. Suleymanlar, G. Yucel (Turkey)*

**T302**

VITAMIN D LC-MS/MS: OPTIMIZATION OF CHROMATOGRAPHIC PARAMETERS TO INCREASED 60% OF COMMERCIAL KIT THROUGHPUT.

*M. Cantù, F. Keller (Switzerland)*

**T306**

SWITCHING FROM IMMUNOASSAY TO LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY (LC-MS/MS) FOR IMMUNOSUPPRESSANT DRUGS DETERMINATIONS.

*C. Castellana, D. Galesi, A. Malagnino, S. Pisa, B. Poppi, A. Tomasi (Italy)*

**T320**

THERAPEUTIC DRUG MONITORING OF 8 NEW ANTICANCER AGENTS BY HIGHPERFORMANCE LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY.

*I. Andriamanana, I. Gana, A. Hulin, B. Duret, C. De Nardi (France)*

**T347**

QUATIFICATION OF HUMAN SERUM HEPCIDIN - 25: EVALUTION OF AN ENZYME-LINKED IMMUNOSORBENT ASSAY VS MASS SPECTROMETRY.

*C. Hansson, G. Dahlfors, P. Barany, P. Stål, J. Marmur, S. Beshara (Sweden)*

**T363**

HOMOGENOUS QUANTITATIVE ANALYSIS OF HUMAN PARATHYROID HORMONE BY USE OF MAGNETIC MARKERS AND SQUID MAGNETOMETER.

*C. Maeda, K. Hisamatsu, K. Mitsuse, S. Egashira, N. Hamasaki, K. Enpuku, H. Kuma (Japan)*



## T373

PROSTATE CANCER URINE PROTEIN PROFILING BY MALDI-TOF/MS: NORMALIZATION, REPRODUCIBILITY AND PRELIMINARY RESULTS.

*A. Padoan, M. La Malfa, D. Basso, C. Zambon, S. Moz, D. Bozzato, P. Fogar, E. Greco, F. Navaglia, G. Pavanello, M. Plebani (Italy)*

## T403

GENETICALLY ENCODED PROTEASE SUBSTRATE BASED ON LANTHANIDE BINDING PEPTIDE FOR TIME-GATED FLUORESCENCE DETECTION.

*J. Vuojola, M. Syrj np  , U. Lamminm  ki, T. Soukka (Finland)*

**12:30 – 14:30**

**Room Suite 1**

**CLINICAL CHEMISTRY WORKSHOP ON PUBLICATION ETHICS  
AND SCIENTIFIC WRITING**

**12:30** Publication ethics

*N. Rifai (USA)*

**13:30** Guide to scientific writing

*T. Annesley (USA)*

**15:00 – 17:00**

**Room Silver**

**IFCC SESSION**

**PUBLIC RELATIONS AND THE VALUE OF LABORATORY MEDICINE**

Chairs: *E. Delvin (Canada), B. Gouget (France)*

**15:00** IFCC public relations: strategy and activities

*E. Jacobs (USA)*

**15:30** Value of the laboratory in clinical medicine

*K. Adeli (Canada)*

**16:00** Demonstrating the value of laboratory tests: a clinical and economic perspective

*B. Jordan (Switzerland)*

**16:30** Role of social media and the internet in education

*P. Veervart (Australia)*

14:30 – 15:30



## Auditorium

Educational Workshop 13 in cooperation with Roche Diagnostics  
**DELIVERING MEDICAL VALUE TO PATIENTS AND PHYSICIANS:  
“DISEASE AREA” SOLUTIONS IN WOMEN’S HEALTH**

Chairs: *J. Creeden (Switzerland), J-C. Forest (Canada)*

**14:30** Early biochemical screening for fetal aneuploidy in the first trimester  
*N. Toerring (Denmark)*

**14:50** Preeclampsia and angiogenic factors: future perspectives in clinical management  
*H. Stepan (Germany)*

**15:10** Cervical cancer screening and diagnosis: how to answer today’s challenges  
*M. Sideri (Italy)*

14:30 – 15:30



## Room Amber 7-8

Educational Workshop 16 in cooperation with Randox Laboratories  
**RAPID DETECTION OF DESIGNER DRUGS WITHIN THE CLINICAL  
LABORATORY**

Chairs: *J. Lamont (UK), S. Pichini (Italy)*

**14:30** - Methods for the rapid detection of synthetic cannabinoids  
*B. Dixon (USA)*

**15:00** Multi-target detection of designer drugs by multiplex immunoassay  
*J. Darragh (UK)*

14:30 – 15:30



## Room Brown 3

Educational Workshop 19 in cooperation with Siemens AG Healthcare Sector

**CHRONIC LIVER DISEASE: A GROWING HEALTH CHALLENGE  
WORLDWIDE**

Chairs: *S. Ignjatovic (Serbia), M. Plebani (Italy)*

**14:30** Advances in diagnosis and management of virus C hepatitis  
*C. Sarrazin (Germany)*

**15:00** Non-invasive technologies and biomarkers for assessment of severity of liver fibrosis  
*W. Rosenberg (UK)*

14:30 – 15:30

## Room Amber 5-6



Educational Workshop 22 in cooperation with Beckman Coulter

### ADVANCES IN HEMATOLOGY

Chairs: *M.C. Béné (France), A. Hammerer-Lercher (Austria)*

14:30 Efficient management of the hematology laboratory activity

*J. Naegelen (USA)*

14:50 Advantages in the hematology laboratory using the HematoFlow solution

*O. Pradier (Belgium)*

15:10 Detection of cell changes in neonatal sepsis by automated white cell morphology

*F. Raimondi (Italy)*

15:45 – 16:45

## Room Brown 1-2



Educational Workshop 42 in cooperation with DiaSorin

### NOVEL BIOMARKERS IN CHRONIC KIDNEY DISEASE

Chairs: *G. Jones (Australia), M. Plebani (Italy)*

15:45 Evaluation of emerging biomarkers in renal disease

*M. Wolf (USA)*

16:15 Measurement of vitamin D metabolites in patients with chronic kidney disease

*J-C. Souberbielle (France)*

16:00 – 17:00

## Room Amber 7-8



Educational Workshop 14 in cooperation with Randox Laboratories

### EMERGING BIOMARKERS IN STROKE

Chairs: *R. Christenson (USA), M. Corsi Romanelli (Italy)*

16:00 Biomarkers in stroke diagnosis, classification and prognosis

*K. Makris (Greece)*

17:30 Towards development of a novel multiplex test for accurate stroke diagnosis employing biochip array technology

*C. Richardson (UK)*

16:00 – 17:00



## Auditorium

Educational Workshop 17 in cooperation with Abbott

### IMPROVING PATIENT OUTCOME THROUGH THE USE OF BIOMARKERS

Chairs: *C. Mueller (Switzerland), M. Zaninotto (Italy)*

**16:00** Early diagnosis of myocardial infarction using highly sensitive troponin I assays

*C. Mueller (Switzerland)*

**16:20** Galectin-3 as a biomarker in heart failure management

*R. de Boer (The Netherlands)*

**16:40** Biomarkers of cardio-renal risk and clinical outcome

*P. Murray (Ireland)*

16:00 – 17:00



## Room Brown 3

Educational Workshop 20 in cooperation with Siemens AG Healthcare Sector

### DIAGNOSIS AND MONITORING OF MULTIPLE MYELOMA AND FREE LIGHT CHAIN DISEASES: WHAT IS NEW IN 2013?

Chairs: *G. Merlini (Italy), J. Tate (Australia)*

**16:00** Laboratory perspectives in the diagnosis and monitoring of plasma cell dyscrasia

*J. Katzmann (USA)*

**16:20** Multiple myeloma in clinical practice: from diagnosis to treatment and follow-up

*O. Decaux (France)*

**16:40** Application of new monoclonal free light chain methods in monitoring monoclonal gammopathies

*D. Ricotta (Italy)*

16:00 – 17:00



## Room Amber 5-6

Educational Workshop 23 in cooperation with Abbott

### QUANTIFYING THE ADDED VALUE OF IN VITRO DIAGNOSTICS (IVD)

Chairs: *P. Jülicher (Germany), C. Price (UK)*

**16:00** Methodological approach to quantify clinical and economic consequences

*L. Annemanns (Belgium)*

**16:30** IVD added value in cardiac surgery

*O. Stanger (UK)*

17:15 – 18:15

## Room Brown 1-2

DiaSorin

Educational Workshop 43 in cooperation with DiaSorin

### **DIAGNOSIS OF CLOSTRIDIUM DIFFICILE INFECTION: CHALLENGES AND CHOICES**

Chairs: *E. Kuijper (The Netherlands), P. Mastrantonio (Italy)*

17:15 Different technical approaches to Clostridium difficile diagnostics  
*F. Barbut (France)*

17:45 The problematic of nosocomial infections by Clostridium difficile  
*M. Delmee (Belgium)*

17:30 – 18:30

## Room Silver

BIO-RAD

Educational Workshop 15 in cooperation with Bio-Rad Laboratories

### **POST-TRANSLATIONAL HEMOGLOBIN ADDUCTS IN THE MANAGEMENT OF DIABETES AND ITS COMPLICATIONS**

Chairs: *A. Lapolla (Italy), I. Young (UK)*

17:30 Laboratory management of diabetic patients carrying hemoglobin disorders  
*D. Sacks (USA)*

17:50 Carbamylated hemoglobin in diabetes and renal diseases  
*P. Gillery (France)*

18:10 Achievement of desirable analytical goals and workflow improvement  
for HbA1c testing: an innovative proposal  
*A. Mosca (Italy)*

17:30 – 18:30

## Room Amber 5-6

mindray  
healthcare within reach

Educational Workshop 18 in cooperation with Shen Zhen Mindray Bio-  
medical Electronics

### **TECHNICAL AND ORGANIZATIONAL SOLUTIONS FOR THE 21ST CENTURY LABORATORY**

Chairs: *J.L. Bedini (Spain), T. Trenti (Italy)*

17:30 A personalized solution for clinical chemistry laboratories  
*M. Plebani (Italy)*

18:00 Managing demand for laboratory testing in a time of economic crisis  
*J.L. Bedini (Spain)*

17:30 – 18:30



## Room Brown 3

Educational Workshop 21 in cooperation with Immunodiagnostic Systems (IDS) Plc

### USE OF THE ALDOSTERONE TO RENIN RATIO TO IDENTIFY PRIMARY ALDOSTERONISM

Chairs: *M. Migliardi (Italy), A. Morganti (Italy)*

17:30 Introduction to renin and aldosterone testing

*A. Morganti (Italy)*

17:50 Plasma aldosterone to renin ratio on an automated analyzer using two novel chemiluminescence immunoassays: one-year experience

*J. Manolopoulou (UK)*

18:10 Analytical considerations on the IDS-iSYS assays for hypertension

*A. Fortunato (Italy)*

17:30 – 18:30



## Room Amber 7-8

Educational Workshop 24 in cooperation with Chromsystems Instruments & Chemicals

### INNOVATIVE SOLUTIONS FOR USING LC-MS/MS IN CLINICAL SETTING

Chairs: *F. Kühlwein (Germany), C. Seger (Austria)*

17:30 Succinylacetone as new parameter in newborn screening

*D. Kasper (Austria)*

18:00 Therapeutic drug monitoring of antiepileptic drugs during pregnancy

*J. Ritchie (USA)*

9:00 – 11:00

**Room Gold**

SYMPOSIUM 9

**BIOMARKERS OF PROSTATE CANCER**

Chairs: *M. Gion (Italy), C. Sturgeon (UK)*

- 09:00** PSA in screening for prostate cancer  
*C. Bangma (The Netherlands)*
- 09:30** Biomarker strategies currently being explored for prostate cancer  
*C. Sturgeon (UK)*
- 10:00** Added value of new tests for prostate cancer detection  
*A. Semjonow (Germany)*
- 10:30** Serum isoform [-2]proPSA derivatives (%P2PSA and PHI) significantly improves the prediction of prostate cancer at initial biopsy in a total PSA range 2-10 µg/L: a multicentric European study  
*M. Lazzeri, A. Haese, A. De La Taille, J. P. Redorta, T. McNicholas, G. Lughezzani, V. Scattoni, V. Bini, M. Freschi, M. Graefen, P. Le Corvoisier, A. Breda, M. Pontillo, F. Ceriotti, G. Guazzoni (Italy)*
- 10:45** Prostate-specific antigen (PSA) and kallikrein-related peptidase 2 (hK2) forms in prostate tissue lysates from radical prostatectomy patients  
*M.T. Peltola, V. Väisänen, K. Alanen, M. Nurmi, K. Pettersson (Finland)*

9:00 – 11:00

**Room Silver**

SYMPOSIUM 10

**NOVEL ASPECTS IN COAGULATION TESTING**

Chairs: *G. Lippi (Italy), S. Sandberg (Norway)*

- 09:00** Genetic and biochemical risk factors for arterial and venous thrombosis: two sides of a coin?  
*A. D'Angelo (Italy)*
- 09:30** Laboratory assessment and monitoring of the new oral anticoagulants  
*E. Favaloro (Australia)*
- 10:00** Standardisation and clinical utility of thrombin-generation assays  
*E. Berntorp (Sweden)*
- 10:30** Simulation of the cost-effectiveness of genetic screening for the susceptibility to oral contraceptive adverse reactions  
*F. Rousseau, J. Duplantie, L. Nshimyumukiza, M. Gagnon, X. Douville, C. Lindsay, M. Parent, E. Bujold, A. Milot, Y. Giguère, C. Gagné, D. Reinharz (Canada)*
- 10:45** Warfarin pharmacogenetic prediction performance: contribution of extended panels of CYP2C9 and VKORC1 genetic variants  
*M. Pelloso, C. Zambon, S. Moz, A. Padoan, P. Fogar, M. Braga, E. Gnatta, R. Padrini, V. Pengo, D. Basso, M. Plebani (Italy)*



9:00 – 11:00

## Auditorium

### SYMPOSIUM 11

#### GASTROENTEROLOGY DISEASE IN 2013

Chairs: *N. Majkic-Singh (Serbia), M. Plebani (Italy)*

- 09:00 Epidemiology of inflammatory bowel disease in children  
*P. Henderson (UK)*
- 09:30 Pathophysiology of inflammatory bowel disease  
*P. Lakatos (Hungary)*
- 10:00 Laboratory testing in inflammatory bowel disease  
*D. Basso (Italy)*
- 10:30 Autoantibodies to glycoprotein 2 (GP2) are associated with disease phenotype in Chron's disease  
*D. Roggenbuck, D. P. Bogdanos, D. Reinhold, T. Wex, A. Forbes, K. Conrad, M. Laass (Germany)*
- 10:45 Autoantibodies directed against components of promyelocytic leukemia protein nuclear bodies in patients with primary biliary cirrhosis  
*A. Bauer, A. Habor, W. Zych, T. Rawa (Poland)*

9:00 – 11:00

## Room Brown 3

### SYMPOSIUM 12

#### NEXT GENERATION SEQUENCING IN LABORATORY DIAGNOSTICS

Chairs: *M. Neumaier (Germany), M. Pazzagli (Italy)*

- 09:00 Genomics, epigenomics and transcriptomics: building an integrated view of disease using next generation sequencing data  
*E. Stupka (Italy)*
- 09:30 Bioinformatics for next generation sequencing: from data management and error correction to medical interpretation  
*T. Rattei (Austria)*
- 10:00 Multigene analysis in the molecular diagnostic of genetic disorders  
*B. Weber (Germany)*
- 10:30 Next generation sequencing in research and diagnostics of genetic cardiomyopathies  
*V. D'Argenio, V. Precone, A. Boccia, G. Limongelli, G. Pacileo, R. Calabrò, G. Paoella, G. Frisso, F. Salvatore (Italy)*
- 10:45 What we don't know about the genetic basis of Brugada syndrome  
*C. Di Resta, A. Pietrelli, R. Bordoni, S. Sala, P. Della Bella, G. De Bellis, S. Benedetti, M. Ferrari (Italy)*

9:00 – 11:00

Room Brown 1-2

IFCC SESSION

**EVIDENCE IN ACTION: TRANSLATING GUIDELINE  
RECOMMENDATIONS INTO CLINICAL PRACTICE**

Chairs: *R. Christenson (USA), A.R. Horvath (Australia)*

**09:00** Does this medical test work better? Effectiveness of HbA1c POCT for management of diabetes

*C. Price (UK)*

**09:30** Determining what works best: the Laboratory Medicine Best Practice Initiative

*R. Christenson (USA)*

**10:00** Translating evidence into practice: successes and challenges

*S. Kahn (USA)*

**10:30** Evidence-based initiatives from New Zealand

*C. Florkowski (New Zealand)*

**Room Gold**

**11:45 - 12:30**

## PLENARY LECTURE

Chair: *F. salvatore (Italy)*

### **Molecular basis and clonal evolution of myeloproliferative neoplasm**

*R. Kralovics (Austria)*



Robert Kralovics, PhD, Robert Kralovics, born 1970, is Czech and joined CeMM on June 1st 2006. He obtained his first degree in Molecular Biology and Genetics in Bratislava and later his Ph.D. in Biophysics at the Academy of Sciences of the Czech Republic in Brno. He did his postdoctoral work on the genetics of myeloproliferative disorders working with Josef Prchal at the University of Alabama at Birmingham, USA. He followed Prchal as an Assistant Professor at the Baylor College of Medicine in Houston.

Since mid 2001 Robert Kralovics has been Project Leader with Radek Skoda in Basel. Robert Kralovics' research interests are in chronic myeloproliferative disorders (MPDs). His major achievement so far has been the identification of a gain-of-function mutation in the JAK2 kinase gene (V617F) that plays an important role in MPD pathogenesis. Prominently published in April 2005 in *New England Journal of Medicine*, the work has given Robert instant celebrity in the hemato-oncological field and fostered Robert's interest in Jak2 as a potential therapeutic target. He received a number of awards including the Lieben Prize in 2010.

In order to encourage discussions, a number of posters have been selected for the Poster Walk Discussion.

The first author of the selected poster is kindly requested to be by the poster panel from 13:00 to 14:00 to present the poster to the coordinator and the audience, within a time limit of max 4 min, plus 2 min for discussion.

## BONE AND JOINT DISEASES

Coordinator: *H. Morris (Australia)*

### W004

ASSESSMENT OF BONE TURNOVER MARKERS FOR THE EARLY DETECTION OF MYELOMA BONE DISEASE RELAPSE.

*J. Brady, A. Hameed, K. Ting, P. O'Gorman (Ireland)*

### W006

IS THE LACTOSE INTOLERANCE A RISK FACTOR TO DEVELOPMENT OF OSTEOPOROSIS AND BONE FRACTURES? GENETIC STUDY IN PERIMENOPAUSAL SPANISH WOMEN.

*I. de Miguel-Elizaga, M. Martínez-Villanueva, J. Noguera-Velasco, N. Varo-Cenarruzabeitia, I. Cebreiros-López, A. Martínez-Ruiz, P. Restituto-Aranguren, S. Botella-Martínez, I. Monreal-Marquiegu, P. Martínez-Hernández (Spain)*

### W009

EVALUATION OF THE PERFORMANCE OF THE NEW AUTOMATED IDS-ISYS 1,25-DIHYDROXY VITAMIN D ASSAY.

*R. Gadsisseur, P. Lukas, A. Carlisi, E. Cavalier (Belgium)*

### W011

TENSION FORCE-INDUCED ATP PROMOTES BONE FORMATION THROUGH P2X7 RECEPTOR IN OSTEOBLASTS.

*T. Kariya, N. Tanabe, C. Shionome, S. Manaka, T. Kawato, M. Maeno, N. Suzuki, N. Shimizu (Japan)*

### W014

HUMAN ERYTHROCYTE'S MEMBRANE AND CYTOSOLIC GLYCOHYDROLASES AS NEW TOOL FOR THE EVALUATION OF OXIDATIVE STRESS IN PATIENTS WITH PROSTHETIC-JOINT-ASSOCIATED INFECTION

*L. Massaccesi, G. Goi, L. Nicola, D. Erba, C. Romanò, L. Drago (Italy)*

### W016

ANGIOTENSIN II INDUCES THE PRODUCTION OF MMP-3 AND MMP-13 THROUGH THE MAPK SIGNALING PATHWAYS VIA THE AT1 RECEPTOR IN OSTEOBLASTS.

*K. Nakai, T. Kawato, N. Tanabe, M. Maeno (Japan)*

### W018

DETERMINATION OF PARATHYROID HORMONE LEVELS BY TWO AND THIRD GENERATION ASSAY.

*E. Plouvier, A. Baccouche, F. Thuillier (France)*

## W019

THE INFLUENCE OF IL1A AND RANK GENE-GENE INTERACTION ON BONE PHENOTYPES.  
*M. Prunk, N. Pristovšek, J. Zupan, J. Marc (Slovenia)*

## W020

DEVELOPMENT OF A PARATHYROID HORMONE BIOCHIP BASED IMMUNOASSAY.  
*P. Stewart, S. Brockbank, C. Richardson, R. McConnell, s. Fitzgerald (UK)*

## W024

MYELOPEROXIDASE AND OXIDATIVE STRESS PARAMETERS IN INFLAMMATORY ARTHRITIDES.  
*G. Uzun, N. Sen, C. Kacar, S. Ozdem (Turkey)*

## CARDIOVASCULAR DISEASE 1

Coordinator: *P. Laitinen (Finland)*

## W036

SERUM URIC ACID AS PREDICTOR OF MORTALITY IN CORONARY ARTERY DISEASE PATIENTS.  
*C. Vassalle, S. Bianchi, P. Landi, C. Prontera, D. Battaglia, A. Vannucci, C. Carpeggiani (Italy)*

## W050

HIGH SENSITIVE CARDIAC TROPONIN T AND COPEPTIN ASSAYS IN THE MANAGEMENT OF PATIENTS PRESENTING WITH CHEST PAIN OF LESS THAN 6 HOURS.  
*D. Collin-Chavagnac, J. Aupetit, T. Perret, G. Lefevre (France)*

## W051

GENETIC CARDIAC SCREENING AMONG HYPERTROPHIC CARDIOMYOPATHY FAMILIES FROM SOUTHERN ITALY.  
*P. Coppola, G. Frisso, S. Zanotta, G. Limongelli, F. Salvatore (Italy)*

## W060

GENETIC PRE-PARTICIPATION SCREENING IN SELECTED ATHLETES: A NEW TOOL FOR THE PREVENTION OF SUDDEN CARDIAC DEATH?  
*G. Frisso, N. Detta, C. Mazzaccara, A. Cordella, G. Limongelli, S. Romano, M. Penco, A. Pelliccia, R. Calabrò, F. Salvatore (Italy)*

## W062

GENE EXPRESSION OF ANTIOXIDANT ENZYMES IN PATIENTS WITH CHAGAS CARDIOMYOPATHY DISEASE.  
*R. Diviani, S. Lioi, G. Gerrard, M.J. Cerutti, J. Beloscar, M. D'Arrigo (Argentina)*

## W063

INTERLEUKIN-15, CORONARY ARTERY DISEASE AND EPICARDIAL ADIPOSE TISSUE: POSSIBLE CORRELATIONS.  
*G. Dogliotti, E. Dozio, E. Vianello, G. Schmitz, M. Corsi Romanelli (Italy)*

## W065

IL-18 LEVEL IN PATIENTS UNDERGOING CORONARY ARTERY BYPASS GRAFTING SURGERY OR VALVE REPLACEMENT: WHICH LINK WITH EPICARDIAL FAT DEPOT?  
*E. Dozio, G. Dogliotti, E. Vianello, G. Schmitz, M. Corsi Romanelli (Italy)*

**W076**

ANALYTICAL PERFORMANCE EVALUATION OF THE ABBOTT DIAGNOSTICS ARCHITECT I2000SR GALECTIN-3.

*D. Gaze, P. Collinson (UK)*

**W096**

INVESTIGATION OF THE PRESENCE AND SEVERITY OF CORONARY HEART DISEASE BY THE 1H NMR-BASED LIPID PROFILING OF ATHEROGENIC AND ATHEROPROTECTIVE PLASMA LIPOPROTEINS.

*C. Kostara, A. Papathanasiou, M. Elisaf, J. Goudevenos, E. Bairaktari (Greece)*

**W131**

INDUCIBLE NITRIC OXIDE SYNTHASE GENE POLYMORPHISM AND ENDOTHELIAL DYSFUNCTION IN CORONARY ARTERY DISEASE.

*R. Dixit, M. Bhatnagar, S. Tyagi, J. Bhattacharjee (India)*

**CARDIOVASCULAR DISEASE 2**

Coordinator: *P. Collinson (UK)*

**W043**

INFLUENCE OF TIME-DEPENDENT DEGRADATION OF CARDIAC TROPONIN T ON INFARCT SIZE ESTIMATION.

*E. Cardinaels, A. Mingels, T. van Rooij, F. Prinzen, M. van Dieijen-Visser (The Netherlands)*

**W052**

EFFECTS OF BERBERINE AND RED YEAST ON PROINFLAMMATORY CYTOKINES IL-6 AND TNF-ALPHA IN MONONUCLEAR CELLS (MNCS) OF HUMAN SUBJECTS.

*B. Covelli, M. Ricciardone, A. Belfiore, C. Benvenuti, P. Mondola, C. Spatuzza, L. Postiglione (Italy)*

**W066**

IMMEDIATE POST-OPERATIVE FALL IN SERUM ALBUMIN IN PATIENTS UNDERGOING CARDIAC SURGERY PREDICTS POOR OUTCOME.

*M. Lum, A. Dunlop, B. Croal (UK)*

**W068**

EXPANSION OF NECROTIC CORE AND SHEDDING OF EXTRACELLULAR DOMAIN OF MERTK RECEPTOR IN HUMAN CAROTID PLAQUES: A ROLE FOR OXIDATIVE DERIVATIVES OF POLYUNSATURATED FATTY ACIDS?

*G. Faccini, A. Pasini, M. Bonetto, C. Gerani, R. Poffe, V. Lavarini, G. Guidi (Italy)*

**W117**

INFLAMMATORY CYTOKINES IN OBSTRUCTIVE SLEEP APNOEA.

*S. Min, S. Bulusu, Y. Ahmed, E. Tsarfati, P. Timms (UK)*

**W136**

ASSOCIATION OF SERIAL CHANGES IN GALECTIN-3 WITH ADVERSE CARDIOVASCULAR EVENTS IN AMBULATORY CHRONIC HEART FAILURE PATIENTS.

*A. Saenger, W. Miller, A. Lueke, D. Grill, A. Jaffe (USA)*

## W138

EVALUATION OF AUTOANTIBODY PREVALENCE IN PATIENTS WITH SUSPECTED MYOCARDIAL INFARCTION WITH IMPROVED IMMUNOASSAY FOR DETECTING AUTOANTIBODIES TO CARDIAC TROPONIN.

*T. Savukoski, P. Laaksonen, S. Wittfooth, T. Ilva, J. Lund, P. Porela, K. Pettersson (Finland)*

## W143

EFFECT OF NATURAL DIETARY SUPPLEMENTS ON ASYMMETRIC DIMETHYLARGININE UNDER PHYSIOLOGICAL CONDITIONS AND IN DISEASE.

*K. Šišková, M. Horváthová, D. Rajdl, L. Pašková, F. Bilka, Z. Ďuračková, J. Muchová, I. Paulíková, J. Racek (Czech Republic)*

## W154

ROLE OF BETA-TRACE PROTEIN IMPROVING THE PREDICTION OF ADVERSE EVENTS IN ATRIAL FIBRILLATION.

*J. Vílchez, F. Marín, S. Manzano-Fernández, F. Avilés-Plaza, S. Parra-Pallarés, H. Fernández, E. Orenes-Piñero, P. Martínez-Hernández, V. Vicente, M. Valdés, V. Roldán (Spain)*

## W158

SOLUBLE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR AS A RISK STRATIFICATION BIOMARKER IN PATIENTS AFTER MYOCARDIAL INFARCTION - PILOT STUDY.

*R. Wlazel, I. Szadkowska, L. Pawlicki, M. Zielinska, M. Paradowski (Poland)*

## DIABETES MELLITUS AND METABOLIC SYNDROME

Coordinator: *A. Mosca (Italy)*

## W162

THE EFFECT OF METFORMIN TREATMENT ON LIPOXIN LEVELS AND INFLAMMATORY MARKERS IN DIABETIC PATIENTS.

*O. Alatas, I. Ertorun, A. Akalin, E. Kurt, M. Bekmez, G. Akalin Ciftci, K. Aksu (Turkey)*

## W164

THE EFFECT OF HAPTOGLOBIN POLYMORPHISM ON THE STATUS ANTIOXIDATIVE ENZYMES IN TYPE 2 DIABETES MELLITUS.

*S. Awadallah, A. Ramadan, M. Nusier (United Arab Emirates)*

## W166

ACCURACY OF THE NOVA STATSTRIP POCT GLUCOSE ANALYZER FOR CLASSIFICATION OF FASTING HYPERGLYCAEMIA IN HIGH-RISK INDIVIDUALS.

*M. Vučić Lovrenčić, S. Božičević, V. Radišić Biljak, E. Pape-Medvidović (Croatia)*

## W168

A NEW GLYCATION GAP BASED ON GLYCATED HAEMOGLOBINE AND GLYCATED ALBUMIN VALUES IN PATIENTS WITH DIABETES.

*J. Rodriguez, S. Rodriguez-Segade, C. Alonso de la Peña, F. Camiña (Spain)*

## W170

EFFECTS OF CETP AND TRIB1 GENE VARIATIONS ON MARKERS OF INSULIN RESISTANCE AND DYSLIPIDEMIA IN BOSNIAN POPULATION.

*S. Semiz, M. Kosatica, T. Dujic, T. Bego, M. Malenica, A. Causevic-Ramosevac, Z. Velija-Asimi, B. Prnjavorac, A. Causevic (Bosnia and Herzegovina)*

## W177

MARKERS OF INFLAMMATION IN TYPE 2 DIABETES PATIENTS WITH AND WITHOUT CHRONIC COMPLICATIONS.

*K. Gawlik, D. Pawlica, B. Kuśnierz-Cabala, U. Grudzień, K. Słowińska-Solnica, B. Solnica (Poland)*

## W180

BIOCHEMICAL AND PHENOTYPE IMPROVEMENT IN SEVERELY OBESE PATIENTS AFTER BARIATRIC SURGERY.

*L. Iaffaldano, C. Nardelli, D. Montanaro, M. Ferrigno, G. Labruna, N. Carlomagno, M. Santangelo, A. Renda, V. Pilone, A. Baldi, P. Forestieri, L. Sacchetti (Italy)*

## W191

CHARACTERIZATION OF MC4R, SIRT1 AND FTO GENE POLYMORPHISMS IN SEVERELY OBESE ITALIAN SUBJECTS: SNP RS9939609 IS ASSOCIATED WITH METABOLIC SYNDROME.

*R. Liguori, G. Labruna, A. Alfieri, E. Farinaro, F. Contaldo, F. Pasanisi, L. Sacchetti, P. Buono (Italy)*

## W202

MEASUREMENT OF CHOLESTEROL PRECURSORS AND CHOLESTEROL IN HUMAN HEPATOMA CELLS AND EFFECTS OF FLAVANONES AND ISOFLAVONES ON CHOLESTEROL BIOSYNTHETIC PATHWAY.

*S. Nakagawa, M. Watanabe, T. Tanaka, S. Yamato (Japan)*

## W203

METABOLIC SYNDROME AND ATHEROSCLEROTIC RISK IN OBESE SUBJECTS.

*C. Novembrino, L. Vigna, R. De Giuseppe, F. de Liso, D. Bignamini, A. Tirelli, C. De Vita, F. Bamonti (Italy)*

## HAEMATOLOGY

Coordinator: *A. Hammerer-Lercher (Austria)*

## W239

ANALYTICAL COMPARISON OF POLYCLONAL VERSUS MONOCLONAL ANTIBODY BASED FREE LIGHT CHAIN (FLC) ASSAYS IN MULTIPLE MYELOMA PATIENTS.

*O. Berlanga, R. Popat, H. Oakervee, C. Williams, C. Craddock, M. Cook J. Cavenagh (UK)*

## W241

14Q32 REARRANGEMENTS IN MULTIPLE MYELOMA.

*T. Boneva, L. Mitev (Bulgaria)*

## W242

SENSITIVITY FOR NON-TUMOR IMMUNOGLOBULIN SUPPRESSION IN IFE AND SPE POSITIVE MULTIPLE MYELOMA MONITORING SAMPLES BY HEVYLITE™ AND TOTAL IMMUNOGLOBULIN.

*L. Traylor, S. LeSourd, K. Sweat, B. Barlogie, S. Usmani, J. Bornhorst (USA)*

## W260

AN EVALUATION OF IMMATURE GRANULOCYTE COUNT AS A BIOMARKER FOR POSTOPERATIVE INFECTION.

*K. Husby, S. Yaqub, M. Helgeland, O. Reiertsen, G. Kravdal, H. Eilertsen, T. Hagve (Norway)*



## W266

THE OPTIMIZATION OF LABORATORY MONITORING OF PRIMARY HEMOSTASIS DURING THE CHRONIC MYELOPROLIFERATIVE DISORDERS.

*N. Kostina, L. Smirnova, G. Kostin (Belarus)*

## W273

CLINICAL UTILITY OF CASE MANAGER SOFTWARE PROVIDED BY THE SYSMEX XE-5000 ANALYZER FOR THE SCREENING OF MICROCYTIC ANEMIA.

*A. Martínez-López de Castro, M. Martínez-Villanueva, J. Noguera-Velasco, M. Schoorl, I. De Miguel-Elizaga, I. Cebreiros-López (Spain)*

## W274

COMPARISON OF THE ANALYTICAL PERFORMANCE OF THE POLYCLONAL ANTIBODY BASED FREELITE AND MONOCLONAL ANTIBODY BASED N LATEX FLC ASSAYS IN SAMPLES FROM PATIENTS WITH MONOCLONAL GAMMOPATHIES.

*P. Chaves Lameiro, J. Gonzalez Alvarado, J. Lázaro de la Osa, I. Camacho Benitez, A. Moro Ortiz, N. Barbosa Carvalho (Spain)*

## W278

THE GENETIC HETEROGENEITY OF BETA GLOBIN VARIANTS IN THE SICILIAN POPULATION.

*C. Passarello, M. Vinciguerra, M. Cannata, F. Cassarà, P. Lo Gioco, F. Leto, A. Maggio, A. Giambona (Italy)*

## W282

BIOLOGICAL PROGNOSTIC FACTORS IN DIFFUSE LARGE B-CELL LYMPHOMA: PRELIMINARY DATA FROM THE MULTICENTRE RANDOMIZED PHASE III CLINICAL TRIAL COMPARING R-HDS VERSUS R-CHOP AS FIRST LINE THERAPY IN HIGH RISK PATIENTS.

*I. Pusceddu, M. Svaldi, M. Tauber, M. Mian, M. Ladetto, G. Gaidano, G. Negri, S. Cortelazzo (Italy)*

## W288

A LABORATORY BASED INTERVENTION TO IMPROVE APPROPRIATENESS OF MONOCLONAL GAMMOPATHIES RELATED TESTING.

*A. Terreni, C. Nozzoli, F. Bergesio, A. Bosi, T. Biagioli, M. Brogi, G. Avveduto, A. Caldini (Italy)*

## HEMOSTASIS

Coordinator: *G. Lippi (Italy)*

## W305

PATIENTS COMPLIANCE FOR A NEW EHEALTH. A VARIETY OF DELIVERY CHANNELS FOR PATIENTS IN ANTICOAGULANT ORAL THERAPY.

*G. Dirienzo, L. Renna, N. Pansini, M. Virgilio, N. Ciavarella (Italy)*

## W307

GALECTIN-1 RECEPTORS IN RESTING HUMAN PLATELETS.

*N. Fink, M. González (Argentina)*

## W312

BENEFICIAL EFFECT OF PHOSPHATIDYLETHANOLAMINE ON PREVENTING VENOUS THROMBO-EMBOLISM: A RAT TAIL THROMBOSIS MODEL EXPERIMENT.

*A. Higashijima, S. Mizunoe, K. Nakahara, H. Kuma, H. Hatae, N. Hamasaki (Japan)*

## W315

AUTOMATION OF LIGHT TRANSMISSION PLATELET AGGREGOMETRY.

*A. Lawrie, K. Kobayashi, P. Lane, I. Mackie, S. Machin (UK)*

## W319

EVALUATION OF THE CHROMOGENIC TEST FOR THE DETERMINATION OF ADAMTS-13 ACTIVITY IN HUMAN PLASMA.

*T. Pajič (Slovenia)*

## W320

CHROMOGENIC Methods MODIFICATION FOR DETERMINATION ANTI XA IN ICTERIC PATIENTS.

*D. Garcia (Argentina)*

## W321

BLOOD CELLS DERIVED MICROPARTICLES AND VASCULAR MARKERS STUDY IN ESSENTIAL THROMBOCYTHAEMIA PATIENTS.

*A. Piccin, I. Pusceddu, L. Marcheselli, C. Murphy, E. Eakins, G. Amadii, C. Moesender Frajria, D. Veneri, O. Perbellini, E. Pacquola, M. Gottardi, F. Gherlinzoni, F. Favaro, D. Faggian, M. Plebani, G. Pizzolo, W. Murphy, S. Cortelazzo (Italy)*

## W324

SIMULATION OF THE COST/EFFECTIVENESS OF PHARMACOGENETIC TESTING PRIOR TO THE INITIATION OF ANTICOAGULO-THERAPY.

*L. Nshimyumukiza, J. Duplantie, M. Gagnon, X. Douville, C. Lindsay, M. Parent, A. Milot, Y. Giguère, C. Gagné, F. Rousseau, D. Reinharz (Canada)*

## W326

PLATELET REACTIVITY IN PATIENTS WITH ACUTE GASTRODUODENAL BLEEDING.

*O. Sulaieva, E. Barinov (Ukraine)*

## W327

OLD PROBLEM – NEW SOLUTION: THE WAY TO DETERM PLATELET AND ENDOTHELIAL DYSFUNCTION IN CEREBROVASCULAR OR CARDIOVASCULAR DISEASES.

*T. Vavilova, A. Laskovets, M. Topuzova, V. Feoktistova, Z. Khushvaktova, A. Lipunova, L. Gaikovaya, O. Sirotkina (Russia)*

## LIVER AND GASTROINTESTINAL DISEASES

Coordinator: *S. Ignjatovic (Serbia)*

## W328

THE NEW ASSAY FAECAL CALPROTECTIN IN RANDOM ACCESS: WHAT CHANGES FOR THE LABORATORY?

*C. Alpini, S. Valaperta, G. Merlini (Italy)*

## W333

HELICOBACTER PYLORI CORRELATION WITH LIPID DISORDERS.

*Gramos Begolli, Luljeta Begolli, Valdete Topçiu, Zana Baruti, Yllka Begolli (Kosovo)*

## W334

KILLER IMMUNOGLOBULIN-LIKE RECEPTOR (KIR) AND HUMAN LEUKOCYTE ANTIGEN (HLA) LOCI PREDICT OUTCOME OF HEPATITIS C VIRUS (HCV)-RELATED HEPATOCELLULAR CARCINOMA (HCC).

*M. Pilli, A. Zerbini, C. Rota, A. Olivani, P. Zanelli, A. Zanetti, T. Trenti, C. Ferrari, G. Missale, E. Cariani (Italy)*

## W337

NEOPTERIN AND CALPROTECTIN: FECAL MARKERS FOR PREDICTING ENDOSCOPIC SEVERITY IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES.

*C. Cuerq, J. Drai, E. Blond, A. Mialon, A. Charlois, B. Flourie, D. Kaiserlian, G. Boschetti, S. Nancey (France)*

## W343

A FURTHER STEP TO IMPROVE THE COST-EFFECTIVENESS OF CALPROTECTIN DETERMINATION.

*S. Ferraro, R. Mozzi, A. Rognoni, D. Basco, M. Panteghini (Italy)*

## W360

APPLICATION OF CALPROTECTIN, NEOPTERIN AND PENTRAXIN 3 IN DIAGNOSTICS OF ULCERATIVE COLITIS AND ASSESSMENT OF DISEASE ACTIVITY.

*D. Pawlica, D. Fedak, B. Kuśnierz-Cabala, I. Cieciko-Michalska, K. Gawlik, U. Grudzień, B. Solnica (Poland)*

## W365

EFFECT OF PIOGLITAZONE, QUERCETIN AND HYDROXY CITRIC ACID ON VASCULAR ENDOTHELIAL GROWTH FACTOR MESSENGER RNA (VEGF MRNA) IN EXPERIMENTALLY INDUCED NON ALCOHOLIC STEATOHEPATITIS (NASH).

*K. Surapaneni, J. Mallika (India)*

## W366

BIOLOGIC VARIATION OF COPPER, CERULOPLASMIN AND COPPER/ CERULOPLASMIN RATIO IN SERUM.

*D. Szóke, F. Braga, C. Valente, M. Panteghini (Italy)*

## W372

AFP-L3 - SCREENING MARKER FOR A HEPATOCELLULAR CARCINOMA IN PATIENTS WITH ALCOHOLIC CIRRHOSIS.

*A. Unic, I. Grgurevic, L. Derek, D. Marijancevic, T. Serdar, Z. Romc (Croatia)*

## W375

EFFECTS OF AMINO ACIDS ON REVERSAL OF AMINOXYACETATEINDUCED METABOLIC DISTURBANCE.

*B. Wang, S. Shiesh (Taiwan)*

## POINT OF CARE TESTING

Coordinator: *D. Bruns (USA)*

### W378

COMPARISON BETWEEN ABL837® RADIOMETER AND DIMENSION VISTA1500® SIEMENS FOR CREATININE MEASUREMENTS.

*M. Callanquin, A. Benmostefa, M. Dehoux, A. Boutten (France)*

### W379

A MICROFLUIDIC UNIT FOR FAST DETECTION OF BACTERIAL DNA AS MENINGITIDIS DIAGNOSTIC AMENDMENT.

*C. Carstens, N. Hlawatsch, T. Brandstetter, C. Gärtner, R. Elbracht (Germany)*

### W380

COMPARATIVE ASSESSMENT OF THE PERFORMANCES OF THE STATSTRIP POINT-OF-CARE TESTING DEVICE FOR THE MEASUREMENT OF KETONE BODIES.

*E. Kaczmarek, E. Guerra, A. Mosca, F. Mastrantonio, F. Lucarelli, F. Valgimigli, F. Ceriotti (Italy)*

### W386

ACCURACY EVALUATION OF TWO BLOOD GLUCOSE MONITORING SYSTEMS ACCORDING TO NEW PREDICTION-ERROR CRITERIA.

*M. Isgrò, R. Morelli, L. Colacicco, C. Zuppi, D. Scribano (Italy)*

### W389

THE FINAL FRONTIER—POINT OF CARE CULTURE!

*G. Kost, P. Katip, K. Vansith, H. Negash (Thailand)*

### W393

EVALUATION OF A NEW HEMATOLOGY AND BLOOD CHEMISTRY ANALYSER SUITABLE AS POINT-OF-CARE TESTING (POCT) IN NEONATAL CARE UNIT: THE MICROSEMI CRP ANALYSER.

*R. Lovero, N. Laforgia, L. Varraso, A. Mileti, E. Mascolo, F. Di Serio (Italy)*

### W396

ESTABLISHING REFERENCE VALUES FOR UMBILICAL CORD VENOUS BLOOD GASES, ELECTROLYTES AND METABOLITES IN OUR HEALTH CARE AREA.

*M. Otero, J. García, J. Paz, M. Calvo, R. España, A. Benítez, C. Alonso (Spain)*

### W399

EVALUATION OF ENDOTOXEMIA LEVEL WITH SHORT-TERM TESTS.

*N. Samsonova, M. Yarustovsky, M. Plushch, E. Rogalskaya, L. Klimovich, O. Podschekoldina (Russia)*

### W402

COMPARATIVE EVALUATION OF TWO POINT OF CARE BLOOD GAS ANALYZERS IN INTENSIVE CARE UNIT.

*A. Schiattarella, A. Primiano, L. Colacicco, C. Zuppi, D. Scribano (Italy)*

### W407

POINT OF CARE TESTING - INDISPENSABLE BUT NOT WITHOUT THE PITFALLS!

*N. Pillay, Y. Ganie, M. Turzyniecka (South Africa)*

**12:30 – 14:30**

**Room Suite 1**

## **CLINICAL CHEMISTRY WORKSHOP ON PUBLICATION ETHICS AND SCIENTIFIC WRITING**

**12:30** Publication Ethics

*N. Rifai (USA)*

**13:30** Guide to Scientific Writing

*T. Annesley (USA)*

**13:00 – 14:00**

**Room Amber 5-6**

## **50th ANNIVERSARY OF CLINICAL CHEMISTRY AND LABORATORY MEDICINE (CCLM)**

Chairs: *F. Ceriotti (Italy), M. Plebani (Italy)*

**13:00** Introductory remarks

**13:05** Past, present and future of CCLM

*M. Plebani (Italy)*

**13:20** CCLM, the Publisher point of view

*W. Boettner (Germany)*

**13:30** The IFCC viewpoint

*G. Beastall (UK)*

**13:45** The EFLM point of view

*I. Watson (UK)*

**15:00 – 17:00**

**Room Silver**

**EFLM SESSION**

## **CLINICAL GUIDELINES AND CARDIAC MARKERS**

Chairs: *M. Graziani (Italy), P. Laitinen (Finland)*

**15:00** Laboratory issues in clinical guideline development

*K. Aakre (Norway)*

**15:30** Guideline from the European Atherosclerosis Society: clinical view on laboratory checklist and issues

*M. Langlois (Belgium)*

**16:00** Cardiac troponin: the sense of more sensitive assays

*M. van Dieijen-Visser (The Netherlands)*

**16:30** Current guidelines on cardiac markers: how should they be introduced and how should the implementation be evaluated

*P. Collinson (UK)*

14:30 – 15:30



## Room Brown 3

Educational Workshop 25 in cooperation with Abbott

### **CURRENT CHALLENGES AND FUTURE OUTLOOK IN SEPSIS TESTING**

Chairs: *J. Bienvenu (France), S. Blincko (Germany)*

14:30 Medical and health-economic challenges of sepsis

*F. Brunkhorst (Germany)*

14:50 Current clinical practice in sepsis testing

*S. Krueger (Germany)*

15:10 Future outlook of sepsis testing

*S. Blincko (Germany)*

14:30 – 15:30



## Room Brown 1-2

Educational Workshop 28 in cooperation with A. Menarini Diagnostics

### **THE IMMUNOFLUORESCENCE TECHNIQUE FOR ANTI-NUCLEAR ANTIBODIES: PRESENT AND FUTURE**

Chairs: *N. Bizzaro (Italy), C. Kallenberg (The Netherlands)*

14:30 Diagnostics of autoimmune disease using indirect immunofluorescence tests for detection of antinuclear antibodies: 60 years old and it does not show

*A. Wiik (Denmark)*

15:00 The use of different technologies for automated detection and classification of anti-nuclear antibodies

*E. Tonutti (Italy)*

14:30 – 15:30



## Room Amber 5-6

Educational Workshop 31 in cooperation with Sysmex Europe

### **NEW APPROACHES IN THROMBOCYTOPENIA MANAGEMENT**

Chairs: *J. Linssen (Germany), S. Rossini (Italy)*

14:30 The clinical relevance of automated modern methods for platelet counting in 2013

*S. Machin (UK)*

15:00 Managing thrombocytopenic samples in the routine workflow

*H.J. Bauch (Germany)*

14:30 – 15:30



## Auditorium

Educational Workshop 34 in cooperation with Tosoh Europe N.V.

### IMPACT OF THE QUALITY OF HbA1c TEST ON ITS CLINICAL USE

Chairs: *A. Mosca (Italy), C. Weykamp (The Netherlands)*

**14:30** HbA1c standardisation is essential for diagnosis and monitoring of diabetes

*G. John (UK)*

**15:00** Quality of HbA1c testing: experience of an IFCC Reference Laboratory

*E. Lenters-Westra (The Netherlands)*

15:45 – 16:45



## Room Amber 7-8

Educational Workshop 44 in cooperation with American Association for Clinical Chemistry (AACC)

### METHOD HARMONISATION: A ROADMAP TO IMPROVED PATIENT CARE

Chairs: *R. Jansen (The Netherlands), G. Myers (USA)*

**15:45** Between-method variability in Laboratory Medicine: the good, the bad and the ugly

*G. Beastall (UK)*

**16:15** From chaos to order: the role of harmonisation

*G. Miller (USA)*

16:00 – 17:00



## Room Brown 3

Educational Workshop 26 in cooperation with The Binding Site Group Limited

### EFFECTIVE MONOCLONAL IMMUNOGLOBULIN MEASUREMENTS USING IMMUNOASSAYS

Chairs: *G. Merlini (Italy), M. Pepys (UK)*

**16:00** Importance of serum free light chain measurements in AL amyloidosis

*A. Wechalekar (UK)*

**16:20** Importance of serum free light chain measurements in kidney disease

*P. Cockwell (UK)*

**16:40** Role of Hevylite from a laboratory perspective

*J. Bornhorst (USA)*

16:00 – 17:00

**ThermoFisher**  
SCIENTIFIC

## Auditorium

Educational Workshop 29 in cooperation with Thermo Fisher Scientific  
**HOW BIOMARKERS MAY IMPROVE AND OPTIMIZE CLINICAL WORKFLOW**

Chairs: *J. Aufenanger (Germany), P. Pezzati (Italy)*

**16:00** The impact of procalcitonin on clinical decision making: why the clinical laboratory should offer procalcitonin testing

*P. Schuetz (Switzerland)*

**16:20** CT-proAVP (copeptin) in the differential diagnosis of the polyuria-polydipsia syndrome

*W. Fenske (Germany)*

**16:40** From theory to practice: saving costs by adding biomarkers to infection management

*M. Wilke (Germany)*

16:00 – 17:00

**SENTINEL**  
DIAGNOSTICS

## Room Brown 1-2

Educational Workshop 32 in cooperation with Sentinel CH  
**STATE OF THE ART OF SCREENING FOR COLORECTAL CANCER**

Chairs: *P. Bossuyt (The Netherlands), M. Plebani (Italy)*

**16:00** Conditions for an effective colorectal cancer screening programme: the French experience

*J. Faivre (France)*

**16:20** Scientific and technical attributes supporting wide adoption of fecal immunochemical tests

*S. Halloran (UK)*

**16:40** Hemoglobin stability in fecal immunochemical test devices: between expectations and reality

*M. Zaninotto (Italy)*

16:00 – 17:00

**sysmex**

## Room Amber 5-6

Educational Workshop 35 in cooperation with Sysmex Europe  
**NEW APPROACHES AND CLINICAL UTILITY OF BODY FLUID EVALUATION**

Chairs: *A. Griesmacher (Austria), J. Linssen (Germany)*

**16:00** New approaches in body fluid management

*C. Fleming (The Netherlands)*

**16:30** The clinical usefulness of automated measurement of body fluids

*R. de Jonge (The Netherlands)*



17:15 – 18:15

**SIEMENS**

**Room Amber 7-8**

Educational Workshop 45 in cooperation with Siemens AG Healthcare Sector

## **CLINICAL APPLICATIONS OF $\beta$ -TRACE PROTEIN (BTP) DETERMINATION**

Chairs: *A. Grubb (Sweden), C. Prumper (Germany)*

**17:15** Quantification of BTP for diagnosis of cerebrospinal fluid leakage  
*A. Huber (Switzerland)*

**17:45** Serum BTP as a marker of residual renal function in dialysis patients  
*T. Shafi (USA)*

17:30 – 18:30

**BIO-RAD**

**Auditorium**

Educational Workshop 27 in cooperation with Bio-Rad Laboratories

## **CHALLENGES AND ADVANCES IN HIV SCREENING AND DIAGNOSIS**

Chairs: *F. Lillo (Italy), B. Link (USA)*

**17:30** Challenges in HIV infection diagnosis  
*S. Laperche (France)*

**17:50** HIV serodiagnosis in 2013  
*T. D. Ly (France)*

**18:10** Enhanced HIV screening through multiplex analysis  
*B. Link (USA)*

17:30 – 18:30

**ThermoFisher  
SCIENTIFIC**

**Room Amber 5-6**

Educational Workshop 30 in cooperation with Thermo Fisher Scientific – ImmunoDiagnostics Division

## **SIMILAR SYMPTOMS, DIFFERENT DISEASES: INCREASED EFFICIENCY THROUGH AN INNOVATIVE APPROACH TO THE PATIENT**

Chairs: *M. Plebani (Italy), G. Zucchelli (Italy)*

**17:30** A better patient outcome with a wide approach algorithm  
*R. Berni Canani (Italy)*

**18:00** A fruitful and efficient model of laboratory organization  
*M. Plebani (Italy)*

17:30 – 18:30

**ThermoFisher**  
SCIENTIFIC

## Room Brown 1-2

Educational Workshop 33 in cooperation with Thermo Fisher Scientific  
**LC-MS TECHNOLOGY FOR CLINICAL TESTING: TIME FOR ACTION?**

Chairs: *C. Kalla (Sweden), P. Wallemacq (Belgium)*

**17:30** Automated, high-throughput workflow for the analysis of 25-hydroxyvitamin D and 3-epi-25-hydroxyvitamin D3 by multiplexed TurboFlow LC-tandem MS

*L. Couchman (UK)*

**18:00** Detection of drugs of abuse in exhaled breath using mass spectrometry and a simple collection device

*O. Beck (Sweden)*

17:30 – 18:30



## Room Silver

Educational Workshop 36 in cooperation with SIBioC WG on Extra Analytical Variability

**IMPORTANT FACTORS FOR QUALITY SPECIMENS: BLOOD DRAWING AND TRANSPORTATION**

Chairs: *O. Sonntag (Germany), T. Trenti (Italy)*

**17:30** The influence of the blood drawing technique

*G. Lippi (Italy)*

**18:00** Pneumatic transport systems: facts and speculations

*D. Giavarina (Italy)*

17:30 – 18:30



## Room Brown 3

Educational Workshop 39 in cooperation with SIBioC WG on Analytical Quality

**PRACTICAL APPROACHES ON MAJOR ISSUES IN TRACEABILITY IMPLEMENTATION**

Chairs: *F. Ceriotti (Italy), L. Thienpont (Belgium)*

**17:30** Approaches to be used in verification of IVD metrological traceability

*F. Braga (Italy)*

**17:50** Current pitfalls of control materials: the way forward

*C. Ottomano (Italy)*

**18:10** How to estimate the measurement uncertainty in clinical laboratories: is the GUM approach mandatory?

*F. Ceriotti (Italy)*

**9:00 – 11:00**

## Room Gold

### SYMPOSIUM 13

#### CONTROVERSIES IN DETECTION AND MONITORING OF DIABETES

Chairs: *E. Kilpatrick (UK), A. Mosca (Italy)*

**09:00** What's diabetes in 2013

*D. Leslie (UK)*

**09:30** HbA1c in the diagnosis of diabetes

*A. Mosca (Italy)*

**10:00** Desirable requirements for POCT for diabetes in hospital settings

*D. Bruns (USA)*

**10:30** HbA1c measurement for the diagnosis of gestational diabetes mellitus: is it useful?

*P. Renz, L. Weinert, G. Cavagnoli, S. Silveiro, J. Camargo (Brazil)*

**10:45** Logistic regression analysis for identifying type 2 diabetics with poor response to sulfonylurea therapy

*N. Nikolac, A. Simundic, A. Saracevic, D. Katalinic (Croatia)*

**9:00 – 11:00**

## Silver Room

### SYMPOSIUM 14

#### LABORATORY ASSESSMENT OF MATERNAL/FETAL UNIT

Chairs: *J.C. Forest (Canada), M. Mussap (Italy)*

**09:00** Non invasive approaches for the genetic analysis of the foetus

*D. Lo (Hong Kong)*

**09:30** Biochemical markers for early pregnancy screening for pre-eclampsia

*J.C. Forest (Canada)*

**10:00** Antenatal screening for Down syndrome

*K. Spencer (UK)*

**10:30** Maternal vitamin B12 levels during the first trimester of pregnancy and influence in newborn screening results

*R. Yahyaoui, A. Dayaldasani, J.F. Ruiz-Escalera, M. Rodriguez-Espinosa, I. Rueda, M.C. Casero, V. Pérez-Valero (Spain)*

**10:45** A 1h-NMR study of bronchopulmonary dysplasia in very low birth weight infants: the contribution of the metabolomic approach

*A. Noto, F. Cibecchini, E. Locci, M. Lussu, F. Murgia, L. Barberini, M.C. Pintus, M.A. Marcialis, R. Irmesi, M. Puddu, V. Fanos (Italy)*

9:00 – 11:00

**Auditorium**

SYMPOSIUM 15

**LABORATORY TESTING IN BONE AND JOINT DISEASE**

Chairs: *A. Griesmacher (Austria), F. Pagani (Italy)*

- 09:00** Laboratory testing in bone disease: an introductory overview  
*R. Eastell (UK)*
- 09:30** How useful is the laboratory in bone and joint disease in the clinical practice?  
*B. Obermayer-Pietsch (Austria)*
- 10:00** The need for standardisation of bone marker assays  
*H. Morris (Australia)*
- 10:30** Difference between total and intact assays for N-terminal propeptide of type I procollagen (P1NP) determination in renal impaired patients  
*E. Cavalier, P. Lukas, N. Ferrante, O. Rousselle, A. Carlisi, P. Delanaye (Belgium)*
- 10:45** Kidney transplantation and osteoporosis, study of genetic susceptibility: influence of vitamin D receptor (VDR) and estrogen receptor (ESR1) genes in relation to bone loss and fracture risk  
*M. Martínez-Villanueva, J. A. Noguera-Velasco, M. J. González-Soriano, M. L. Gil-del Castillo, I. Tovar-Zapata, L. Jimeno-García, P. Martínez-Hernández (Spain)*

9:00 – 11:00

**Room Brown 3**

SYMPOSIUM 16

**EMERGING ISSUES IN SEPSIS**

Chairs: *J. Bienvenu (France), G. Merlini (Italy)*

- 09:00** Sepsis: epidemiological and clinical aspects  
*J.L. Vincent (Belgium)*
- 09:30** New concepts in pro-/anti-inflammatory response in sepsis  
*G. Monneret (France)*
- 10:00** Emerging biomarkers for targeted and tailored therapy in sepsis  
*J. Pugin (Switzerland)*
- 10:30** A new rapid, easy and cost-effective method that identifies unknown pathogenic microorganisms within 3 h from sample collection  
*H. Niimi, T. Ueno, S. Hayashi, M. Mori, H. Tabata, H. Minami, S. Saito, I. Kitajima (Japan)*
- 10:45** Presepsin (sCD14-ST) is an early predictor of outcome in patients with severe sepsis or septic shock. Preliminary data from the Albumin Italian Outcome Sepsis (ALBIOS) study  
*S. Masson, P. Caironi, E. Spanuth, R. Thomae, R. Fumagalli, A. Pesenti, M. Romero, G. Tognoni, R. Latini, L. Gattinoni (Italy)*

**9:00 – 11:00**

**Room Brown 1-2**

**SYMPOSIUM 17**

## **LABORATORY MANAGEMENT AND PATIENT SAFETY**

Chairs: *W. Huisman (The Netherlands), A. Simundic (Croatia)*

**09:00** The new edition of ISO 15189 with emphasis on patient safety aspects  
*W. Huisman (The Netherlands)*

**09:30** Laboratory medicine quality indicators and patient safety  
*M. Plebani (Italy)*

**10:00** Issues on laboratory management in the Arab Region  
*G. Shannan (Syria)*

**10:30** Use of standardised algorithms with clinical decision rules and D-dimer testing in clinical practice to aid in the diagnostic work-up for suspected venous thromboembolism: a study in 7 European countries  
*A.H. Kristoffersen, E. Ajzner, D. Rogic, E. Sozmen, P. Carraro, A.P. Faria, J. Watine, P. Meijer, S. Sandberg, EFLM WG on Post-Analytical External Quality Assurance*

**10:45** Alert value reporting in primary care setting: a new strategy for patient safety  
*M. Salinas, M. Lopez-Garrigos, A. Asencio, J. Lugo, M. Gutierrez, A. Santo-Quiles, L. Flors, C. Leiva-Salinas (Spain)*

## **AWARDING CEREMONY**

**11:10 – 11:40**

**Room Brown 3**

### **AWARDING CEREMONY**

Awarded groups will be recognised in the following order:

- Milan Bursary Programme recipients
- Congress Bursary recipients
- The Binding Site Italia Awards
- Posters Awards
- IFCC-Roche Travel Scholarships

Room Gold

11:45 - 12:30

PLENARY LECTURE

Chair: *M. Plebani (Italy)*

**Acute coronary syndrome: the present and future role of biomarkers**

*B. Lindahl (Sweden)*



Bertil Lindahl, MD, PhD is Professor in Cardiology, Uppsala University and the Director of Uppsala Clinical Research Centre. Dr. Lindahl is the author of more than 130 peer reviewed original articles and more than 45 review articles or book chapters, mainly in the field of biochemical markers and risk stratification in acute coronary syndrome. He has served on a number of national and international committees including the Task Force for the Universal Definition of Myocardial Infarction and the Committee for the National Guidelines for Cardiac

Care, The National Board of Health and Welfare. He has also participated in the scientific advisory boards for a number of diagnostic companies. Dr. Lindahl has received research grants from the Swedish Heart-Lung Foundation and the Swedish Foundation for Strategic Research. He is member of the Swedish Society of Cardiology and Fellow of the European Society of Cardiology.

# CLOSING CEREMONY

## Room Gold

12:30 - 13:00

### CLOSING CEREMONY

- 12:30** Closing remarks  
EUROMEDLAB Milano 2013 President, *M. Panteghini (Italy)*  
IFCC President, *G. Beastall (UK)*  
EFLM President, *I. Watson (UK)*
- 12:50** Welcome to Paris  
EUROMEDLAB Paris 2015 Co-President and COC Chair, *B. Gouget (France)*
- 13:00** Farewell Paris Party

Thursday 23



# EUROMEDLAB PARIS 2015

21-25 JUNE 

 **EVOLUTION IN LABORATORY MEDICINE**

## 21<sup>st</sup> IFCC - EFLM European Congress of Clinical Chemistry and Laboratory Medicine

EuroMedLab JIB – 2015 exhibition  
22-24 June 2015

PARIS, FRANCE – Le Palais des Congrès  
21-25 June 2015





# CLOSED MEETINGS

Legenda:

C=Committee

WG=Working Group

TF=Task Force

Friday 17 May 2013	Chair	Time	Room	Level
Joint Meeting Executive Boards: IFCC and EFLM		9:00-11:00	Suite 1	2
IFCC Executive Board		13:00-17:00	Suite 1	2
EFLM Executive Board		14:00-17:00	Suite 2	2

Saturday 18 May 2013	Chair	Time	Room	Level
IFCC Executive Board		9:00-17:00	Suite 1	2
EFLM Executive Board with the participation of C Chairs		9:00-16:30	Suite 2	2
IFCC Scientific Division - Executive Committee	I. Young	9:00-17:00	Suite 3	2
IFCC Education and Management Division - Executive Committee	M. Ferrari	9:00-17:00	Suite 4	2
IFCC Communications and Publications Division - Executive Committee	K. Adeli	9:00-17:00	Suite 5	2

Sunday 19 May 2012	Chair	Time	Room	Level
IFCC Executive Board		9:00-12:30	Suite 1	2
IFCC TF-Paediatric Laboratory Medicine	V.L. Grey	9:00-12:30	Office 16	1 (balcony)
IFCC Communications and Publications Division - Executive Committee	K. Adeli	9:00-12:30	Suite 5	Mezzanine
EFLM General Assembly		9:00-13:00	Amber 5-6	2
IFCC TF-Impact of Laboratory Medicine on Clinical Management and Outcomes	M. Hallworth	9:00-17:00	Suite 2	2
IFCC Scientific Division - Executive Committee	I. Young	9:00-17:00	Suite 3	2
IFCC Education and Management Division - Executive Committee	M. Ferrari	9:00-17:00	Suite 4	2
IFCC Standardisation of Carbohydrate-Deficient Transferrin (WG-CDT)	F. Schellenberg	9:00-17:00	Hotel Melià outside MiCo	
IFCC C-Reference Intervals and Decision Limits	K. Ichihara	10:00-17:00	Suite 6	Mezzanine
EFLM WG-Cardiac Markers	P. Laitinen	12:00-17:00	Office 15	1 (balcony)
IFCC C-Congresses and Conferences	T. Ozben	13:00-17:00	Office 16	1 (balcony)
EFLM C-Education and Training Chair meets representatives of EFLM National Societies	E. Topic	13:30-15:00	Suite 1	2
IFCC C-Internet and e-Learning	P. Vervaart	13:30-17:00	Suite 5	Mezzanine
EFLM C-Science Chair meets representatives of EFLM National Societies	S. Sandberg	14:00-16:00	Amber 5-6	2
EFLM C-Quality and Regulation Chair meets representatives of EFLM National Societies	W. Huisman	15:00-16:30	Suite 1	2

Monday 20 May 2012	Chair	Time	Room	Level
IFCC C-Reference Intervals and Decision Limits	K. Ichihara	9:00-11:30	Suite 5	Mezzanine
IFCC Corporate Members Meeting	T. Brinkmann	9:00-10:00	Suite 1	2
IFCC C-Distance Learning	J. Smith	9:00-12:00	Office 15	1 (balcony)
IFCC C-Traceability in Laboratory Medicine	A. Kessler	9:00-12:00	Suite 3	2
IFCC WG-CSF Proteins	K. Blennow	9:00-12:00	Suite 6	Mezzanine
EFLM WG-Test Evaluation	R. Horvath	9:00-17:00	Suite 2	2
IFCC C-Analytical Quality	E. Amann-J. Gill	9:00-17:00	Office 16	1 (balcony)
IFCC TF-Pharmacogenetics	R. van Schaik	10:00-13:00	Suite 4	2
IFCC Developing Quality Competence in Medical Laboratory Project	M. Thomas	12:00-13:30	Suite 5	Mezzanine
IFCC TF-Chronic Kidney Disease	G. Jones	12:30-14:30	Suite 6	Mezzanine
EFLM C-Education and Training	E. Topic	13:00-14:00	Office 15	1 (balcony)
IFCC C-Standardization of Thyroid Function Tests	L. Thienpont	13:30-15:30	Suite 3	2
EFLM WG-Continuous Postgraduate Education	G. Sypniewska	14:00-16:00	Office 15	1 (balcony)
IFCC TF-Pharmacogenetics, IFCC Laboratory PGx Network (Open)	R. van Schaik	14:00-15:30	Suite 5	Mezzanine
IFCC WG-Quality Specifications for Glucose POCT	R. Tirimacco	14:00-17:00	Suite 4	2
SIBioC-Pre-natal Screening of Trisomy 21	C. Dall'Amico	15:00-17:00	Suite 1	2
IFCC WG-CSF Proteins	K. Blennow	15:00-18:00	Suite 6	Mezzanine
EFLM WG-Distance Education	D. Gruson	16:00-17:30	Office 15	1 (balcony)
SIBioC-Laboratory Allergology	B. Dente	16:00-18:00	Suite 3	2
SIBioC-Diagnostic Applications and Quality Control of Clinical Molecular Biology	E. Capoluongo	16:30-18:30	Suite 5	Mezzanine

Tuesday 21 May 2013	Chair	Time	Room	Level
EFLM WG-Biological Variation	B. Bartlett	8:30-10:30	Office 16	1 (balcony)
IFCC WG-eJIFCC	G.L. Kovács	8:30-10:30	Suite 1	2
SiBioC-Clinical Pharmacotoxicology and Doping	S. Pichini	8:30-10:30	Suite 3	2
SiBioC-Clinical Biochemistry and Cardiovascular risk factors	A. Clerico	8:30-10:30	Suite 6	Mezzanine
EFLM C-Profession	S. Zerah	9:00-11:00	Suite 5	Mezzanine
IFCC WG-Harmonisation of Autoantibody Tests	J. Sheldon	9:00-15:00	UNIMI outside MiCo	
IFCC WG-Standardisation of Pregnancy-Associated Plasma Protein A	K. Pettersson	9:00-17:00	Suite 4	2
IFCC Communications and Publications Division: Meeting of Editors	K. Adeli	10:30-12:00	Suite 1	2
SiBioC-Urine Test (GSIEU)	F. Manoni	11:00-13:00	Suite 3	2
EC4 Foundation Board	S. Zerah	11:00-13:00	Suite 5	Mezzanine
SiBioC-Analytical Quality	C. Ottomano	11:00-13:00	Suite 6	Mezzanine
EFLM WG-Guidelines	W. Oosterhuis	11:00-13:30	Office 16	1 (balcony)
Scientific Committee EFLM-UEMS Congress	I. Watson	13:00-14:30	EFLM booth	
IFCC WG-Allowable Errors for Traceable Results	R. Bais	13:00-14:30	Suite 2	2
IFCC C-Reference Systems of Enzymes	F. Ceriotti	13:30-17:30	Suite 3	2
IFCC TF-Point of Care Testing	R. Tirimacco	14:00-17:00	Suite 6	Mezzanine
SiBioC-Laboratory of Hemostasis and Thrombosis	E. Ascari / B. Morelli	14:30-16:30	Office 16	1 (balcony)
EFLM WG-Postanalytical External Quality Assurance	E. Ajzner	14:30-17:30	Suite 2	2
EC4 Register Commission	S. Zerah	15:00-18:00	Suite 5	Mezzanine
IFCC TF-Clinical Applications of Cardiac Bio-Markers	J. Ordoñez-Llanos	15:00-18:00	Suite 1	2

Wednesday 22 May 2013	Chair	Time	Room	Level
IFCC TF-Young Scientists	D. Gruson	8:00-10:00	Office 16	1 (balcony)
EFLM WG-Accreditation and ISO/CEN standards	M. Vaubourdolle	8:30-10:30	Suite 2	2
IFCC WG-AETR: meeting with IVD companies	R. Bais	9:00-10:30	Suite 1	2
IFCC WG-Clinical Quantitative Mass Spectrometry Proteomics	S. Lehmann	9:00-11:00	Suite 4	2
IFCC TF-Ethics	D. Bruns	9:00-11:00	Suite 5	Mezzanine
IFCC C-Clinical Laboratory Management	J. Krahn	9:00-12:00	Office 15	1 (balcony)
IFCC C-Public Relations	E. Delvin	9:00-16:00	Suite 3	2
EFLM WG-IVD Directive	W. Huisman	10:30-11:30	Suite 2	2
SiBioC-Biochemical markers of bone rearrangements	F. Pagani	10:30-12:30	Office 16	1 (balcony)
IFCC WG-eNews	T. Pillay	12:00-13:30	Suite 2	2
IFCC TF-Young Scientists Network (Open Meeting)	D. Gruson	12:00-13:30	Suite 5	Mezzanine
IFCC WG-Serum Parathyroid Hormone	C. Sturgeon	12:00-14:00	Suite 4	2
CCLM Celebration		13:00-14:00	Amber 5-6	2
SiBioC-Mass Spectrometry: application and diagnostic innovations	S. Persichilli	14:00-16:00	Suite 5	Mezzanine
IFCC C-Molecular Diagnostics	D. Payne	14:00-17:30	Suite 2	2
EFLM C-Science	S. Sandberg	14:30-17:00	Suite 4	2
IFCC C-Evidence Based Laboratory Medicine	R. Christenson	15:00-17:00	Suite 1	2
SiBioC-Diabetes Mellitus	A. Mosca	16:00-18:00	Suite 5	Mezzanine
SiBioC-Tumour Markers	M. Gion	16:30-18:30	Suite 3	2
SiBioC-Evidence-based Laboratory Medicine	T. Trenti	17:00-18:30	Suite 1	2
IFCC C-Clinical Molecular Biology Curriculum	M. Neumaier	12:00-17:00	HSR outside MiCo	

Thursday 23 May 2013	Chair	Time	Room	Level
EFLM WG-Patient Focused Laboratory Medicine	I. Watson	8:30-10:30	Office 15	1 (balcony)
EFLM WG-Personalised Laboratory Medicine	M. Pazzagli	8:30-10:30	Office 16	1 (balcony)
EFLM WG-Common Training Frameworks / Syllabus	G. Wieringa	8:30-10:30	Suite 3	2
SiBioC-Clinical Biochemistry of Biological Fluids other than Blood	G. Bernardi	8:30-10:30	Suite 5	Mezzanine
IFCC WG-Ibero-American Nomenclature and Translations	M. Blanes-Gonzalez	9:00-12:00	Suite 1	2
EFLM WG-Recognition of Professional Qualifications. Liaison with European entities	J.P. Brochet	10:30-12:30	Suite 3	2
SiBioC-Proteins	G. Merlini	11:00-13:00	Suite 2	2
SiBioC-Laboratory Statistics	M. Vidali	11:00-13:00	Suite 4	2
SiBioC-Hematology Diagnostics	A. La Gioia	11:00-13:00	Suite 5	Mezzanine





## Focus where it matters - delivering healthcare innovation to improve patient care

*Meet Roche Diagnostics at the IFCC-Euromedlab, Milan 2013*

Please take the opportunity to visit our scientific symposia and experience a program full of highlights presented by respected experts in various fields of disease and diagnostics.

We are looking forward to meeting you at our Booth 65 and sharing opinions about how laboratory medicine can deliver innovation in patient management and patient care.

**Roche  
exhibition  
booth  
Nr. 65**



**cobas**<sup>®</sup>  
*Life needs answers*

# RANDOX



Visit us at  
**Stand 079**  
SAVING LIVES THROUGH EARLY  
INTERVENTION AND DIAGNOSIS

## Innovating quality diagnostic solutions

Randox has over 30 years experience in the diagnostic industry, providing revolutionary solutions to laboratories worldwide. Our products ensure diagnostic testing is efficient whilst offering the highest level of accuracy and quality for reliable patient diagnosis.

### Quality Reagents

Comprehensive menu of the highest quality routine and specialised tests

### Multiplexing Biochip Array Technology

Simultaneous detection of multiple markers from a single sample for a complete patient profile

### Clinical Chemistry Analysers

The RX series will provide ultimate consolidation, flexibility, reliability and quality

### Quality Management Solutions

Complete solutions including internal quality controls, external quality assessment schemes (EQA) and online peer group reporting

# RANDOX

Randox Laboratories Limited, 55 Diamond Road, Crumlin, County Antrim, BT29 4QY, United Kingdom

T +44 (0) 28 9442 2413 F +44 (0) 28 9445 2912 E [marketing@randox.com](mailto:marketing@randox.com) I [www.randox.com](http://www.randox.com)



**SIEMENS**

Visit Us at IFCC  
Booth #38

Scan for Details



# Test smarter. Run faster.

Siemens answers help fight disease and improve productivity by uniting clinical and workflow excellence.

[siemens.com/test-smarter-faster](https://www.siemens.com/test-smarter-faster)

Clinical diagnostics testing is part science and part **business**—and overall performance depends on how well they work together.

Siemens harnesses the power of both by combining the extensive menu of tests you want with the **leading-edge** technology you need to run them most efficiently.

Not only do we deliver assays that support your clinical excellence in detecting and **fighting disease**, we commit all our technical know-how to developing innovative workflow solutions that increase your productivity.

What's more, Siemens provides the education, services, and support to keep science and business running at their absolute best—so you can test smarter. **And run faster.**

Find out how at [siemens.com/test-smarter-faster](https://www.siemens.com/test-smarter-faster).

**Answers for life.**



# SPEED FORWARD PERFORMANCE FORWARD LAB FORWARD

**Your lab is the foundation of patient care  
and we'll never stop partnering with you  
to move it forward.**

Beckman Coulter has always been uniquely committed to advancing and optimizing your lab.

We share your commitment to providing uncompromising service to physicians and patients.

That's why we remain focused on innovative and reliable solutions to improve your lab performance.

***Move your lab forward with Beckman Coulter.***







**WHAT CAN THE  
DESIGN OF A  
CAR'S INTERIOR  
TEACH US ABOUT**

**laboratory  
solutions?**

For one thing, sophisticated systems, thoughtfully designed, can simplify tasks and streamline operation. The intuitive placement of displays and controls in natural sightlines and within easy reach can minimize distraction and enhance driver comfort.

As we shift the development of Abbott Diagnostics' next-generation laboratory solutions into high gear, we too are factoring in the human. Around the globe and across the healthcare continuum, customers have consistently expressed a desire for the simplification of critical interactions: Between individuals, instruments, and information.

By rethinking those interactions, by factoring the healthcare professional into the design of our newest solutions, we can improve access to and leverage the value of diagnostics to enhance care.

**Factoring in  
the Human.**



**DISCOVER MORE  
AT THE ABBOTT  
BOOTH #43**

Factoring in the Human, is a trademark of  
Abbott Laboratories in various jurisdictions.  
© 2013 Abbott Laboratories MS\_13\_4331 v1.0

See how the human is factored in at  
[FactoringintheHuman.com](http://FactoringintheHuman.com)

 **Abbott**  
A Promise for Life

# The Clinical Chemistry Trainee Council

**NEW!**

**It's even easier to be a part of it!**



Sign up for free with our new one-step registration at [traineecouncil.org](http://traineecouncil.org)

Now available –

In español at [traineecouncil.org/spanish](http://traineecouncil.org/spanish)

In Chinese at [traineecouncil.org/chinese](http://traineecouncil.org/chinese)

In Portuguese at [traineecouncil.org/portuguese](http://traineecouncil.org/portuguese)

**Even more content –**

- Pearls of Laboratory Medicine
- CouncilChat
- Podcasts
- Webcasts
- Q&As
- Clinical Case Studies

